Today, we announced that the European Commission has granted marketing authorization in the EU for a treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). Visit our website to learn more. investor.incyte.com/press-releases
Incyte
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. More on Wikipedia
-
Incyte
@Incyte
-
Incyte
@Incyte
We're excited to join the hematology community at #ash26! Explore the data we'll be presenting and follow along for updates from the meeting. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Read our press release to learn about our Q3 financial results and business updates, including progress across our portfolio. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Learn more from Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development, on the progress being made across our GI oncology portfolio at #esmo26. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Incyte shared new data from our KRAS G12D and TGFβR2xPD-1 programs in PDAC and MSS CRC at #esmo26. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat.
Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #solveon incyte.com/our-science -
Incyte
@Incyte
We’ve announced a clinical trial collaboration with @Genmab for patients with first-line metastatic colorectal cancer (CRC) harboring a KRAS G12D mutation. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At #esmo26, Incyte will share new data from our oncology portfolio. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
From our booth to sessions at the #eadvcongress, it was exciting to connect with the global dermatology community and share the latest in inflammation and autoimmunity.
-
Incyte
@Incyte
There’s more to vitiligo than what appears on the skin.
A deeper understanding of the condition and the experiences of people living with it is essential to continued progress. Learn more about Incyte’s work to address patient needs through science and innovation. -
Incyte
@Incyte
There’s more to vitiligo than what appears on the skin.
A deeper understanding of the condition and the experiences of people living with it is essential to continued progress. Learn more about Incyte’s work to address patient needs through science and innovation. -
Incyte
@Incyte
At this year’s #eadvcongress we’ll join researchers, clinicians and advocates from around the world to discuss how a deeper understanding of immune-mediated skin conditions can help advance research and patient care. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release.
-
Incyte
@Incyte
Here’s a look at where data from the Incyte portfolio will be throughout this year’s #eadvcongress. We look forward to connecting with the dermatology community and advancing important scientific conversations. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Join us at the upcoming European Academy of Dermatology and Venereology (EADV) Congress where we will share our latest scientific advancements in inflammation and autoimmunity. Learn more about our data. #eadvcongress investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We're attending the @nbd_foundation's 78th Annual Bleeding Disorders Conference (BDC) in Orlando, August 13–15. Our team is excited to listen to, learn from and connect with the bleeding disorders community. #bdc2026
-
Incyte
@Incyte
Patients guide our work in dermatology. Hervé Lamarque, Division Vice President, Head of Business Unit Inflammation & Autoimmunity (IAI) International, shares how Incyte’s commitment to the global dermatology community helps shape our research and innovation. investor.incyte.com/news-releases/news-release-details/op…
-
Incyte
@Incyte
Atopic dermatitis (AD) is a chronic inflammatory skin disease that can affect daily life. Learn more about AD and our commitment to patients. investor.incyte.com/news-releases/news-release-details/op…
-
Incyte
@Incyte
Incyte announces @EU_Commission approval of our topical JAK treatment for adults with moderate atopic dermatitis. Read to learn more. investor.incyte.com/news-releases/news-release-details/op…
-
Incyte
@Incyte
Read our press release to learn more about Incyte’s Q2 financial results and business updates. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’ll be presenting data from our Oncology pipeline at the @myESMO 2026 Congress in Madrid. Highlights include updates from our KRAS G12D inhibitor in pancreatic cancer and our TGFβR2×PD-1 bispecific antibody in colorectal cancer. Join us at #esmo26 to explore the data and what’s next across our oncology portfolio. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re focused on building a portfolio of scientifically differentiated compounds designed to make a meaningful impact for patients.
Learn more about von Willebrand disease (VWD), the most common inherited bleeding disorder, and the data presented at this year’s #isth2026 Congress. investor.incyte.com/news-releases/news-release-details/in… -
Incyte
@Incyte
Data from our Phase 1/2 multidose study in von Willebrand disease (VWD) was presented at the @isth Congress. Learn more about the data. #isth2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Approximately 135,000 people in the U.S. are living with von Willebrand disease (VWD). Learn more about this condition and our commitment to advancing therapies for diseases with significant unmet need. investor.incyte.com/news-releases/news-release-details/in…
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Today, we completed our acquisition of Vega Therapeutics, expanding our hematology portfolio into bleeding disorders by adding a differentiated late-stage program for von Willebrand disease (VWD). Read our press release to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Pablo Cagnoni reflects on the importance of the new data we shared for our mutCALR-targeted monoclonal antibody in patients with myeloproliferative neoplasms (MPNs) at the @EHA_Hematology Congress. #eha2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We shared new positive data for our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) and essential thrombocythemia (ET) at the @EHA_Hematology Congress. Learn more about these data. #eha2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We are proud to share Phase 3 data at the @EHA_Hematology Congress, underscoring our commitment to advancing care for patients with diffuse large B-cell lymphoma (DLBCL). Learn more. #eha2026 investor.incyte.com/news-releases/news-release-details/re…
-
Incyte
@Incyte
Today, the prestigious Plenary Abstracts Session at the @EHA_Hematology Congress highlighted data from the Phase 3 frontMIND trial for patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Learn more. #eha2026 investor.incyte.com/news-releases/news-release-details/re…
-
Incyte
@Incyte
We're sharing data from our Hematology portfolio at this year's @EHA_Hematology Congress. Check out our press release for more details and stay tuned for updates. #eha2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re looking forward to presenting data from our Hematology portfolio at this year’s @EHA_Hematology Congress! Read our press release to learn more. #eha2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Incyte announced an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of @Star_biotech, strengthening our hematology portfolio and expanding our work into bleeding disorders. Read more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Learn more from Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development, as he discusses the significance of the Phase 3 frontMIND data for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), shared at this year’s @ASCO Meeting. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today at the American Society of Clinical Oncology® (@ASCO) Annual Meeting we shared new data from the pivotal frontMIND trial in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL), simultaneously published in @TheLancet. Learn more. #asco26
-
Incyte
@Incyte
Explore data from our oncology portfolio being presented at the American Society of Clinical Oncology® (@ASCO) Annual Meeting. #asco26 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Incyte to present the latest data from our oncology portfolio at the upcoming American Society of Clinical Oncology® (@ASCO) Annual Meeting. Learn more. #asco26 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Our purpose remains constant: delivering meaningful medicines for patients. Incyte continues to advance with real momentum and a clear plan for long-term growth and innovation. Learn more. incyte.com/our-stories/incyte-in-2026
-
Incyte
@Incyte
Incyte and @genesismolai are expanding our collaboration designed to accelerate the discovery of potential new medicines. Learn more. investor.incyte.com/news-releases/news-release-details/in…
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Excited for our partnership with Edison Scientific. Read more here: investor.incyte.com/news-releases/news-release-details/in…
Sam Rodriques
@SGRodriques
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
We are excited to announce a strategic collaboration with @EdisonSci to employ the Kosmos AI platform across Incyte's discovery and development lifecycle. Read more. investor.incyte.com/news-releases/news-release-details/in…
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Incyte will be presenting data from our Hematology and Oncology pipeline at the 2026 @EHA_Hematology Congress in Stockholm. Stay tuned for updates and read more about our data. #eha2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At this year’s #eadvsymposium, we shared data in patients with moderate atopic dermatitis (AD). Learn more about these data. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At Incyte, we’re committed to advancing research and solutions to help address patient needs and preferences. We are proud to announce the @US_FDA approval of a new, once-daily formulation of our therapy for MPNs and GVHD. Learn more. incyte.com/what-we-do/hematology-oncology
-
Incyte
@Incyte
Learn more about Incyte’s latest @US_FDA approval of a bioequivalent, once-daily formulation of our therapy for patients living with certain types of myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We are excited to welcome David Brooks, M.D., who joins #teamincyte today as Group Vice President of Global Medical Affairs. David brings deep medical leadership experience, and a strong perspective on the critical role Medical Affairs plays in advancing care.
-
Incyte
@Incyte
Welcome to #teamincyte, Nicole Katz! Nicole joins as Group Vice President, Head of Global Corporate Affairs, and is a seasoned global communications and corporate affairs leader with more than 25 years of experience across a broad range of therapeutic areas.
-
Incyte
@Incyte
Please join us in welcoming Suketu (Suky) Upadhyay to #teamincyte! Suky was recently appointed Executive Vice President and Chief Financial Officer (CFO). He brings extensive experience in the healthcare sector and a strong track record of leading high-performing finance organizations. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
The @US_FDA has approved a once-daily formulation of our treatment for patients with certain types of myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). Read our press release to learn more about this significant milestone. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
As shared this morning during our Q1 2026 earnings call, we announced positive Phase 3 results from our STOP-V clinical trial program in adult patients with nonsegmental vitiligo. Read our press release to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Read our press release for Incyte’s Q1 2026 financial results and business updates. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re headed to @ASCO where new data from our oncology portfolio will be presented. Read our press release to learn more about our presence at #asco26. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At @AADskin’s Annual Meeting we presented new data in hidradenitis suppurativa, atopic dermatitis and vitiligo. #aad2026 incyte.com/what-we-do/inflammation-and-autoimmunity
-
Incyte
@Incyte
At the @AADskin’s Annual Meeting, we presented new late-breaking 54-week data for patients with moderate to severe hidradenitis suppurativa (HS). Learn more. #aad2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Join Incyte at the @AADskin 2026 Annual Meeting this weekend to explore how Incyte is advancing innovation in dermatology for patients. Learn more. #aad2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Learn more about the new late-breaking 54-week hidradenitis suppurativa (HS) data and other abstracts being presented from our dermatology portfolio at this year’s @AADskin Annual Meeting. #aad2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Incyte to present new data from its dermatology portfolio at the @AADskin Annual Meeting. #aad2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: Incyte receives approval of a treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) from the @EU_Commission. Read to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Read our press release for Incyte’s Q4 and FY2025 financial results and updates on our key clinical programs. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At the @JPMorgan Healthcare Conference this week, we shared how we’re transforming into a high-growth company. Download the presentation and listen to the recording here. #jpm2026 investor.incyte.com/events/event-details/44th-annual-j-p-…
-
Incyte
@Incyte
Incyte to present updates on our business, pipeline progress and upcoming milestones at the 44th Annual @jpmorgan Healthcare Conference. #jpm2026 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’ve announced positive topline results from the Phase 3 frontMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Read our press release to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for certain patients with squamous cell carcinoma of the anal canal (SCAC). Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved our new targeted immunotherapy combination for adults with relapsed or refractory follicular lymphoma (FL). Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We are committed to driving innovation in hematology, with research spanning multiple types of cancer, including follicular lymphoma (FL). Learn more about FL. incyte.com/what-we-do/hematology-oncology
-
Incyte
@Incyte
#news: The @EU_Commission approved a new therapy for certain adults with relapsed or refractory follicular lymphoma (FL). Read our press release to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#ash25 brought together the brightest minds in hematology to share breakthroughs, connect with peers and advance patient care.
Thank you @ASH_hematology for fostering innovation and collaboration that drives the field forward! -
Incyte
@Incyte
New data evaluating our novel first-in-class mutCALR-targeted monoclonal antibody in patients with essential thrombocythemia (ET) at #ash25. @ASH_hematology investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Discover insights into our mutant calreticulin (mutCALR)-targeted monoclonal antibody for patients with essential thrombocythemia (ET). investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today, we presented updated data for patients with essential thrombocythemia (ET) at #ash25. Learn more by reading our press release. @ASH_hematology investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
What is mutCALR and what does it do? Learn more from Pablo J. Cagnoni, M.D., President and Head of Research & Development at Incyte, about the research behind our mutCALR-targeted monoclonal antibody. #ash25 incyte.com/what-we-do/hematology-oncology
-
Incyte
@Incyte
We’re at #ash25! Follow along for the latest updates from #teamincyte, live from Orlando.
-
Incyte
@Incyte
At Incyte we’re committed to transforming the treatment of blood cancers, especially for patients with myeloproliferative neoplasms (MPNs).
Hear from our CEO, Bill Meury, as he discusses the myelofibrosis (MF) data presented at #ash25. Learn more. @ASH_hematology -
Incyte
@Incyte
Learn more about the data we presented at #ash25 evaluating our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF). @ASH_hematology investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re proud to share that the @FDA has granted Breakthrough Therapy designation to our first-in-class mutCALR-targeted monoclonal antibody. Read more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today, we announced new data evaluating our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) at #ash25. Read the press release to learn more. @ASH_hematology investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re bringing the latest data from our oncology portfolio to the @ASH_hematology Annual Meeting! 🩸 Stay tuned for updates live from Orlando. #ash25 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Join us at the @ASH_Hematology Annual Meeting and Exposition, where we will present data from our hematology portfolio. Learn more about our upcoming data and stay tuned for updates at #ash25. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Incyte is heading to the @hsforg Symposium on Hidradenitis Suppurativa Advances (SHSA), where we are looking forward to engaging with the dermatology community and sharing our latest findings. #shsa2025 shsa.joynsymposium.com/conference/
-
Incyte
@Incyte
Read the press release for our Q3 financial results and business updates. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’ve announced a strategic partnership with @EnableInjection for the enFuse® on-body delivery system. Learn more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We presented data for patients with moderate atopic dermatitis (AD) at the 15th Georg Rajka International Symposium on Atopic Dermatitis (ISAD). Visit our website to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re proud to be named a Top 5 Biotech & Pharma Employer by @ScienceMagazine! Our secret? The passion and perseverance of our team to #solveon for patients every day. 💙
-
Incyte
@Incyte
Hear from Jim Lee, Group Vice President, Head of Inflammation and Autoimmunity, as he discusses the importance of the data presented at this year’s #eadvcongress.
-
Incyte
@Incyte
This year’s #eadvcongress was an inspiring meeting full of innovation, expert insights and meaningful connections.
-
Incyte
@Incyte
Explore updates from our dermatology portfolio at the @EADV Congress, including late-breaking data for patients with hidradenitis suppurativa (HS). #eadvcongress
-
Incyte
@Incyte
Incyte shared data for patients with hidradenitis suppurativa (HS) at this year’s @EADV Congress. Read our press release to learn more. #eadvcongress
investor.incyte.com/news-releases/news-release-details/in… -
Incyte
@Incyte
We will share data from our pipeline at the #eadvcongress, including late-breaking 24-week results in hidradenitis suppurativa (HS). Join us in Paris at @EADV (European Academy of Dermatology and Venereology) or read our latest press release.
-
Incyte
@Incyte
We have welcomed Soni Basi, Ph.D. to #teamincyte! Soni has been appointed Executive Vice President and Chief Human Resources Officer, bringing with her over 25 years of experience in global HR and business leadership.
-
Incyte
@Incyte
We've announced our Q2 financial results and shared updates on our key clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re excited to welcome Bill Meury as Incyte’s new President & CEO. With 30+ years of industry experience and enterprise leadership, Bill will guide Incyte into its next chapter of innovation and growth. Thank you to Hervé Hoppenot for 11+ years of transformative leadership—we wish him all the best in retirement.
investor.incyte.com/news-releases/news-release-details/in… -
Post not available here, view on X
Incyte
@Incyte
We are committed to redefining the treatment of myeloproliferative neoplasms (MPNs) by continuing to push the boundaries of what’s possible for patients living with these rare and chronic blood cancers. #eha2025
This media couldn't be displayed. See it on the original post.
Incyte
@Incyte
As a leader in MPN therapies, we're advancing a novel, first-in-class and potentially disease-modifying treatment for these rare blood cancers, including essential thrombocythemia (ET). Learn more. #eha2025
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Positive data for our novel, first-in-class mutant CALR-targeted therapy in patients with essential thrombocythemia (ET) were presented at the @EHA_Hematology Congress. #eha2025
-
Incyte
@Incyte
We’ve announced a global partnership with @QIAGEN to develop a multimodal next generation sequencing (NGS) companion diagnostic to support our portfolio of investigational medicines for MPNs, including our novel, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989.
Learn more: investor.incyte.com/news-releases/news-release-details/qi… -
Incyte
@Incyte
Learn more about the positive data we shared on our novel, first-in-class mutant calreticulin (mutCALR) targeted monoclonal antibody in patients with essential thrombocythemia (ET) at the @EHA_Hematology Congress. #eha2025
investor.incyte.com/news-releases/news-release-details/po… -
Incyte
@Incyte
#news: @TheLancet has published data from the Phase 3 POD1UM-303 trial evaluating our treatment for patients with squamous cell anal carcinoma (SCAC). Read the press release to learn more.
-
Incyte
@Incyte
We’re looking forward to the @EHA_Hematology Congress this weekend, where we will present the latest findings from our hematology/oncology portfolio. Learn more. #eha2025
-
Incyte
@Incyte
We're sharing new data at the @EHA_Hematology Congress, including the first clinical data on our first-in-class targeted monoclonal antibody in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). Stay tuned for updates at #eha2025.
-
Incyte
@Incyte
We’re headed to the @EHA_Hematology Congress where we will be presenting data from our oncology portfolio. Read our press release to learn more. #eha2025
-
Incyte
@Incyte
At Incyte, our people make us who we are. We work hard to build a culture where different perspectives are valued, and everyone has a voice. We're proud to be named a Global Most Loved Workplace by @Newsweek! #incyteproud #solveon
-
Incyte
@Incyte
We’re honored to be named a @Newsweek Global Most Loved Workplace for the third year in a row! This recognition reflects our award-winning culture—where every employee helps to make a difference in the lives of patients. #solveon #mostlovedworkplace
-
Incyte
@Incyte
Incyte is dedicated to supporting patients with critical unmet needs, like squamous cell carcinoma of the anal canal (SCAC). Learn more about the significance of our recent approval in SCAC.
-
Incyte
@Incyte
#news: We've reported our Q1 financial results, along with updates on our key clinical programs. Read more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Join Incyte at the American Association for Cancer Research (@AACR) Annual Meeting to learn more about our #oncology portfolio and how we are advancing cancer solutions. #aacr25 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
This week at the @AADSkin Annual Meeting, we presented key data highlighting the latest insights into the impact and treatment of vitiligo at the Global Vitiligo Foundation (@StepUp4Vitiligo) Scientific Symposium. Learn more. #aad2025
-
Incyte
@Incyte
We’re excited to begin recruitment for our new Incyte U.S. Product Strategy/Marketing postdoctoral fellowship program in partnership with Saint Joseph’s University (@saintjosephs). We’re proud to support Pharm.D. and Ph.D. graduates cultivate professional growth. #solveon
-
Incyte
@Incyte
We’ve announced a strategic AI-focused collaboration with Genesis Therapeutics focused on the research, discovery and development of novel small molecule medicines. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We've reported our Q4 and year-end 2024 financial results, along with updates on our key clinical programs. Read more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We've announced the FDA approval of 9mg and 22mg vials of Niktimvo in partnership with @Syndax. Read our press release to learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We are #incyteproud to be named to @Newsweek’s list of America’s Greatest Workplaces for Diversity 2025! This honor reflects our commitment to a diverse, inclusive environment that drives innovation. #solveon
-
Incyte
@Incyte
Congratulations to our chairman and CEO, Hervé Hoppenot, on being named a Delaware 222 Honoree by @DeBusinessTimes for the second year in a row! His visionary leadership and contributions have greatly impacted Delaware's business community. Congrats, Hervé!
-
Incyte
@Incyte
#news: Positive late-breaking data from the pivotal Phase 3 inMIND trial was presented at the @ASH_hematology Annual Meeting evaluating a treatment for patients with relapsed or refractory follicular lymphoma (FL). Learn more. #ash24
-
Incyte
@Incyte
Steven Stein, M.D., Executive Vice President and Chief Medical Officer at Incyte, is driven by our mission to develop innovative medicines for patients. Read his reflections on the Incyte research presented at the @ASH_Hematology Annual Meeting. #ash24
-
Incyte
@Incyte
Data from our pivotal Phase 3 study for an investigational treatment option for patients with non-small cell lung cancer (NSCLC) was presented today at the @myESMO Asia Congress. Learn more about the results. #esmoasia2024
-
Incyte
@Incyte
This weekend, join us at the @ASH_Hematology Annual Meeting to explore how Incyte’s innovative science is advancing solutions for patients. Learn more about our #oncology portfolio at #ash24.
-
Incyte
@Incyte
We're proud to announce that our CFO, Christiana Stamoulis, has been named one of the Top 25 Biotech CFOs by Top CFOs! Her contributions are critical to our work to find solutions for patients by following the science.
-
Incyte
@Incyte
The @ASH_Hematology Annual Meeting is just around the corner, where we will be presenting data from our #oncology portfolio. Explore our data and stay tuned for updates at #ash24.
-
Incyte
@Incyte
At Incyte, we’re all in for a sustainable future. Discover our ESG goals and our commitment to reaching carbon neutrality by 2025. Let’s make an impact together! #americarecyclesday
-
Incyte
@Incyte
#teamincyte showed up strong at the @PennWomen’s 2024 Pennsylvania Conference for Women where we enjoyed inspiring talks, new connections and a celebration of community accomplishments. #solveon
-
Incyte
@Incyte
This #nationalstemday, we asked a #teamincyte scientist to share her personal journey in STEM. Peg Squier, Group Vice President of US Medical Affairs at Incyte, shares her thoughts about the importance of the day. #solveon
-
Incyte
@Incyte
This #nationalfamilycaregiversmonth, we recognize that being a caregiver means something different to everyone. Whether it's offering support or providing care, each act is invaluable. Share your caregiving stories with us below.
-
Incyte
@Incyte
We are excited to announce the second year of our Moments of Clarity program, which continues our commitment to highlighting the stories of people living with eczema, like Emily. Discover more about Emily’s story and the Moments of Clarity program.
-
Incyte
@Incyte
We've announced our Q3 financial results and shared updates on our key clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We're thrilled to have been recognized as a top five employer by @ScienceMagazine for the seventh year in a row! Our strength lies in the collective experience, passion and perseverance of our team as we work to #solveon for patients.
-
Incyte
@Incyte
We are #incyteproud to announce that Incyte has been awarded the 2024 Pete du Pont Freedom Award, accepted by Hervé Hoppenot, Incyte's President and CEO. This award reaffirms our company’s outstanding innovative vision and influential role in the Delaware business community.
-
Incyte
@Incyte
Incyte Biosciences Canada announced that @GovCanHealth has granted a Notice of Compliance for the first non-steroidal topical JAK inhibitor, treating mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older. Learn more.
-
Incyte
@Incyte
Everyone’s journey with #atopicdermatitis is different. Listen to Keri Kelley, Senior Outreach & Community Manager at @eczemaresearch, share what she’s learned over the years, and where parents of children with eczema can find resources.
-
Incyte
@Incyte
We are proud to announce that Steven Stein, Incyte’s Executive Vice President and Chief Medical Officer, has been recognized as a 2024 @PharmaVoice 100 Honoree. This award highlights Steven’s influential role in following the science and finding solutions for patients.
-
Incyte
@Incyte
How much do you know about atopic dermatitis? This #nationaleczemaawarenessmonth, learn more about the most common form of eczema, which affects 10% of adults globally.
-
Incyte
@Incyte
We are committed to advancing science for patients, regardless of the size of the patient population. Hear from patients diagnosed with cholangiocarcinoma (CCA), a rare cancer that forms in the bile ducts, to understand what inspires us to #solveon. #rarecancerday
-
Incyte
@Incyte
#news: Data from our dermatology portfolio will be presented at the 2024 @EADV Congress. Read our latest press release to learn more about data at #eadv2024. investor.incyte.com/news-releases/news-release-details/mu…
-
Incyte
@Incyte
Representing 10% of leukemia cases, chronic myeloid leukemia (CML) continues to affect many lives around the world. Learn about the significant impact of CML. #worldcmlday #solveonforbloodcancer #bloodcancerawarenessmonth
-
Incyte
@Incyte
Watch how Marilyn’s myeloproliferative neoplasm (MPN) symptoms come to life through vivid AI imagery, revealing #theunseenjourney of what it’s like to live with her #mpn. #solveonforbloodcancer
-
Incyte
@Incyte
Squamous cell anal carcinoma (SCAC) is the most common type of anal cancer. Discover more about this condition and explore how we are working to support this patient community.
-
Incyte
@Incyte
September 15 marks the beginning of #hispanicheritagemonth, a time for us to recognize, honor and reflect on the great influence Hispanic Americans have on our society. Hear from our colleagues on what this month means to them.
-
Incyte
@Incyte
Test your knowledge of the different types of lymphoma and discover how Incyte is dedicated to advancing research in these types of blood cancers. #worldlymphomaawarenessday #solveonforbloodcancer #bloodcancerawarenessmonth
-
Incyte
@Incyte
We partnered with @nationaleczema to highlight the experiences of patients with atopic dermatitis and the need for treatment options. #worldatopiceczemaday
-
Incyte
@Incyte
Over the past year, we have made significant progress toward advancing our Global Responsibility initiatives. We are confident the coming year will mark another remarkable chapter in our journey as we continue to advance our commitments to create a healthier future.
-
Incyte
@Incyte
Ben’s world changed when a bone marrow biopsy revealed he had a myeloproliferative neoplasm (#mpn). With the help of AI-generated imagery based on his symptoms, Ben hopes to raise awareness of MPNs and empower others. #mpnawarenessday #theunseenjourney #solveonforbloodcancer
-
Incyte
@Incyte
Applications open on October 1 for Incyte’s postdoctoral fellowship programs in partnership with Saint Joseph’s University (@saintjosephs). We’re proud to offer these programs to Pharm.D. and Ph.D. graduates to cultivate professional growth and Solve On.
-
Incyte
@Incyte
Today, we are at the @SocietyofHemOnc Annual Meeting, where we will present our recent findings in #hematology. Learn more. #soho2024.
-
Incyte
@Incyte
How much do you know about leukemia? We're breaking down the facts about this blood cancer and the impact it can have on patients. Join #teamincyte on #worldleukemiaday and learn more. #solveonforbloodcancer #bloodcancerawarenessmonth
-
Incyte
@Incyte
This #bloodcancerawarenessmonth, we are steadfast in our mission to educate and raise awareness about these serious diseases. Join us this September in our dedication to #solveonforbloodcancer.
-
Incyte
@Incyte
We've announced our Q2 financial results and shared updates on our major clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
This weekend, we’re presenting at the @SocietyPedsDerm Annual Meeting, where we will be sharing updates from our #dermatology portfolio, including atopic dermatitis (AD) and vitiligo research. Learn more.
-
Incyte
@Incyte
Our Head of Global Communications, joined other biopharma leaders on @FiercePharma panel to discuss the importance of prioritizing and engaging employees to build a vibrant workplace. Learn more about our company culture by visiting our website.
-
Incyte
@Incyte
At Incyte, we are devoted to transforming patient lives, including those with dermatologic conditions. This #worldskinhealthday, we're promoting #skinhealthforall by sharing facts on various skin conditions.
-
Incyte
@Incyte
As #pridemonth comes to a close, our team is reflecting on the importance of allyship and advocacy for the LGBTQIA+ community year-round! 🏳️🌈
-
Incyte
@Incyte
Understanding vitiligo goes beyond surface-level knowledge, which is why we continue to #solveonforvitiligo every day at Incyte. Delve into the complexities of this condition, exploring what's happening within the skin on #worldvitiligoday. #solveon incyte.com/our-stories/the-science-within-the-skin
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
The Incyte Ingenuity Awards in Vitiligo™ are back! We’re now accepting submissions for 2024. We’re also proud to introduce the new Vitiligo Innovators Program™, recognizing those who have made a positive impact on people living with vitiligo. Learn more about our U.S. programs.
-
Incyte
@Incyte
Announcing our Incyte Ingenuity Award (IIA) in Vitiligo™ recipients! 👏 Congratulations to @UMassChan and @LittyLigo Vitiligo Community Network.
We applaud their well-deserved recognition! Learn more about how these projects aim to help those living with vitiligo. #solveon -
Incyte
@Incyte
Vitiligo is a life-long condition that results in white patches on the skin. What happens within the skin to cause loss of pigment? Understanding the processes of depigmentation and repigmentation in vitiligo may help people understand and manage the autoimmune condition.
-
Incyte
@Incyte
We are headed to the upcoming @EHA_Hematology Annual Meeting where we will share the latest data in #hematology. Learn more. #eha2024
-
Incyte
@Incyte
Yesterday at the @RevAtopicDerm 2024 Conference, we shared data from our 52-week maximum use study for a treatment option for patients with atopic dermatitis. Learn more. #rad24
-
Incyte
@Incyte
We’re at the @RevAtopicDerm 2024 Conference! Stay tuned for updates on data from our #dermatology portfolio at #rad24.
-
Incyte
@Incyte
Living with vitiligo can present unique challenges, but finding community and connection through shared experiences can be empowering. Hear the stories of people living with this condition and share your own POV. #solveonforvitiligo #solveon
-
Incyte
@Incyte
Join us in embracing and uplifting the LGBTQIA+ community as we celebrate #pridemonth! 🏳️🌈 Our team is dedicated to fostering an inclusive environment, and we invite you to discover more about our commitment to diversity and acceptance. #solveon
-
Incyte
@Incyte
The depigmentation process in vitiligo is complex and takes time. Watch to learn more about the science within the skin for those living with vitiligo. #solveonforvitiligo #solveon
-
Incyte
@Incyte
On #nationalcancersurvivorday, we're honoring the strength and resilience of those impacted by cancer. Today serves as a reminder of the ongoing needs within the cancer community and our commitment to #solveon for patients. #ncsd2024
-
Incyte
@Incyte
What is vitiligo? This #vitiligoawarenessmonth, we’re working to raise awareness of this chronic autoimmune condition and educate on the complex process of depigmentation. Listen to #teamincyte share the facts about vitiligo. #solveonforvitiligo #solveon
-
Incyte
@Incyte
We’re happy to announce the completion of Incyte’s acquisition of Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists. Read the press release to learn more.
-
Incyte
@Incyte
On #worldbloodcancerday, we pause to acknowledge the profound impact these cancers have on patients worldwide. With approximately 1.24 million cases reported globally each year, it is crucial that we work to find solutions for patients impacted by blood cancers. #solveon
-
Incyte
@Incyte
We are excited to announce that #teamincyte has once again been recognized as a @Newsweek Global Most Loved Workplace for the second consecutive year. #incyteproud #solveon
-
Incyte
@Incyte
We’re proud to announce that Hervé Hoppenot, Incyte’s President and CEO, has been named the winner of the 2024 PACT Enterprise Life Sciences CEO of the Year Award by @PhilaPACT! This award is a testament to his remarkable leadership and innovative vision. Congratulations, Hervé!
-
Incyte
@Incyte
Today, we are excited to announce the expansion of our presence in the heart of Wilmington with the acquisition of two new facilities. This significant step highlights our dedication to community engagement and fostering local innovation. Learn more. #incyteproud #solveon
-
Incyte
@Incyte
Congratulations to Pamella Galluzzi de Castro and Susan Spitz who received the @HBAnet Rising Star and Luminary awards, respectively. It was an honor to celebrate you this weekend! #hbaimpact #hbawoty24
-
Incyte
@Incyte
We are focused on fostering a collaborative, innovative and inclusive culture that is rooted in diverse experiences, perspectives and backgrounds. This month, we recognize #aapiheritagemonth and the significant contributions of the AAPI community at Incyte.
-
Incyte
@Incyte
At Incyte, our commitment to impact goes beyond our offices. We are dedicated to supporting patients, as well as the local communities where we live and work. Learn more about how we are giving back to the community.
-
Incyte
@Incyte
At Incyte, our drive to push the boundaries of innovation and find solutions for patients with cancer is core to who we are. Learn more about our efforts in oncology. #nationalcancerresearchmonth #solveon
-
Incyte
@Incyte
We’ve reported our Q1 financial results and provided updates on key clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
On #fopawarenessday we support efforts to raise awareness of Fibrodysplasia Ossificans Progressiva (FOP), a very rare genetic connective tissue disorder.
-
Incyte
@Incyte
#news: Today, we announced an agreement to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists. Read more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
This #worldhealthday, Steven Stein, Chief Medical Officer at Incyte, shares his perspective on the work Incyte is doing to advance health for patients with critical medical needs. To learn more about how we support patients, visit our website. #solveon
-
Incyte
@Incyte
Congratulations to our CEO, Hervé Hoppenot, for being recognized as an inaugural Delaware 222 Honoree by @DeBusinessTimes! His leadership has made a significant impact and this recognition highlights his influential role in Delaware's business community.
-
Incyte
@Incyte
Pamella Galluzzi de Castro and Susan Spitz have been honored with the prestigious @HBAnet Rising Star and Luminary awards, respectively. Congratulations to Pamella and Susan for their dedication to #solveon and their profound impact on patients’ lives. #hbaimpact #hbawoty24
-
Incyte
@Incyte
#news: Late-breaking data from our Phase 2 study focused on an investigational therapy for patients with prurigo nodularis has been presented today at @AADSkin. Learn more. #aad2024 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today at the @AADSkin Annual Meeting, we are excited to share data from our Phase 2 study for an investigational treatment option for patients with hidradenitis suppurativa. Learn more. #aad2024 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
On #internationalwomensday, we celebrate the significant achievements of women around the world and the perspectives of #teamincyte. We are committed to supporting ongoing efforts to #inspireinclusion in the workplace. #iwd2024 #solveon
-
Incyte
@Incyte
We’re presenting at the @AADSkin Annual Meeting! Learn more about our #dermatology portfolio and research being shared this weekend. #aad2024
-
Incyte
@Incyte
#news: Multiple abstracts from our growing dermatology portfolio will be presented at the @AADskin Annual Meeting. #aad2024 investor.incyte.com/news-releases/news-release-details/ne…
-
Incyte
@Incyte
To our incredible team: Thank you for your hard work and dedication. Every day, you bring your best, push boundaries and contribute to impacting the lives of patients. #employeeappreciationday #solveon
-
Incyte
@Incyte
We’re proud to raise awareness of rare diseases like myeloproliferative neoplasms (#mpns). This #rarediseaseday, we’re helping make #theunseenjourney of symptoms seen through generative AI. Learn more at www.theunseenjourney.com.
-
Incyte
@Incyte
#rarediseaseday reminds us of our commitment to find innovative solutions for patients. Our scientists work tirelessly to make meaningful discoveries, regardless of the disease or size of the patient population. #solveonforpatients #solveon
-
Incyte
@Incyte
#news: The @US_FDA has accepted for Priority Review the Biologics License Application for a potentially differentiated treatment for chronic graft-versus-host disease (#gvhd). Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
On #nationalcaregiversday we honor those who selflessly, generously and compassionately care for people with complex diseases. Watch Pedro and Jessica talk about their heroes. #solveonforpatients #solveon
-
Incyte
@Incyte
This #blackhistorymonth, we proudly shine a light on the remarkable individuals from #teamincyte who are part of the National Pan-Hellenic Council (NPHC), also known as the Divine Nine. Together, we honor the past, embrace the present and shape a brighter future.
-
Incyte
@Incyte
Introducing the ChOLLECTIVE: an initiative that amplifies the voice of the cholangiocarcinoma (#cca) community and brings people together through shared experiences. Watch Karli and Matt’s inspiring story. #worldccaday #solveonforpatients #solveon
-
Incyte
@Incyte
We’ve reported our Q4 and year-end 2023 financial results and provided updates on key clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
On International Day of Women and Girls in Science, we're proud to highlight the incredible contributions of our talented scientists at Incyte. Their passion, expertise and dedication are driving innovation and transforming the field of medical research.
-
Incyte
@Incyte
We work to change patients’ lives for the better and on #worldcancerday, we’re reminded of our goal to transform the treatment of cancer. #solveonforpatients #solveon
-
Incyte
@Incyte
Today kicks off #ccaawarenessmonth, which raises awareness for the cholangiocarcinoma community. We show support for the @CCA_Alliance efforts to #beclearoncca and encourage healthcare professionals to make the diagnosis journey easier for patients. #solveonforpatients #solveon
-
Incyte
@Incyte
#news: Today, we’re at the 42nd Annual @JPMorgan Healthcare Conference, where we'll be discussing our pipeline and commitment to pushing the boundaries of scientific innovation. #jpm24 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Anna's #eczema symptoms followed her throughout school, impacting her favorite activities. Anna shared her story with @TheMandyMoore, who also lives with eczema. Read more about our partnership with Mandy Moore on the #momentsofclarity program. incyte.com/our-stories/moments-of-clarity
-
Incyte
@Incyte
It’s been an exciting few days at the @ASH_hematology Annual Meeting! Check out how #teamincyte has been learning and discussing new research across the #oncology and #hematology space.
-
Incyte
@Incyte
#news: New positive data was featured in today’s @ASH_hematology Plenary Scientific Session from the AGAVE-201 trial evaluating a treatment for patients with refractory chronic graft-versus-host disease (GVHD). Learn more. #ash23 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#ash23 kicks off this weekend. Learn more about key presentations from across our #oncology portfolio at @ASH_hematology. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Tonight, CURE® and @VoicesofMPN came together to recognize the heroes who have made a difference in the lives of patients with myeloproliferative neoplasms (MPNs). Learn more about the program and the 2023 class of MPN Heroes®. incyte.mpnheroes.com
-
Incyte
@Incyte
We've made it our mission to create a workplace that fosters collaboration, inspires innovation and puts the well-being of #teamincyte first. Learn more about Incyte's award-winning culture and dedication to #solveon from our employees.
-
Incyte
@Incyte
Pedro is living with cholangiocarcinoma (#cca) with his wife and caregiver, Ángela, who supports him through the ups and downs of his CCA journey. Hear their story at www.facebook.com/testmycholangio/videos/1766437937161595/ #nationalfamilycaregivermonth #nfcmonth
-
Incyte
@Incyte
From all of us at #teamincyte, we wish you a happy and healthy #thanksgiving.
-
Incyte
@Incyte
At Incyte we are working toward a more sustainable future. On #americarecycles Day, learn more about our ESG commitment and goals. incyte.com/responsibility
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
This #nationalsteamday, we asked #teamincyte scientists, "What ignites your interest in the field?" We hope their answers inspire future innovators looking ahead in their careers in #science. Learn more.
-
Incyte
@Incyte
At Incyte, every employee plays a role in making a difference in the lives of patients. Together, we celebrate our scientific advances and progress towards our shared mission to #solveon and we are proud to recently be ranked #2 among @ScienceMagazine’s Top Biopharma employers.
-
Incyte
@Incyte
The @ASH_hematology Annual Meeting is quickly approaching, where data from our #oncology portfolio will be presented. Excited to share these advances toward addressing patients’ needs. #ash23 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Living with #vitiligo hasn't been easy for Kim. While she faced various obstacles, she learned how to overcome these challenges and share her story. Read more about Kim’s experience and hear from others living with the condition. www.bustle.com/life/two-women-living-with-vitiligo-share-…
-
Incyte
@Incyte
We’re proud to have been ranked #2 on @ScienceMagazine’s 2023 Top Employers list! Learn more at www.science.org/content/article/making-happy-workplace-em…
Science Careers
@ScienceCareers
The verdict is out! The 2023 Top Employers survey has captured insights from 6,800 professionals in #biotech, #pharma & #biopharma, revealing their priorities when choosing an employer. Click to explore the results! #sctopemployers
www.science.org/content/article/making-happy-workplace-em… -
Incyte
@Incyte
We’re proud to announce that two Incyte products have been recognized as nominees for Best Pharmaceutical Agent at the #prixgalien awards by the @GalienFdn. Congratulations to this year’s winner and other fellow nominees!
-
Incyte
@Incyte
We're humbled and excited to have been acknowledged as one of @ScienceMagazine's #sctopemployers for the sixth year in a row! Our incredible team is dedicated to our science, innovation and patient-focused mission to #solveon. www.science.org/content/article/making-happy-workplace-em…
-
Incyte
@Incyte
Learn more about the data presentations from our Oncology portfolio at the European Society for Medical Oncology (@myESMO) Annual Meeting. #esmo investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Vitiligo is a skin condition that affects melanin production in the body, resulting in discolored patches on the skin. During the #eadvcongress we will share new research with the scientific community. Learn more at www.thisisvitiligo.com.
-
Incyte
@Incyte
#news: Today, we announced data focused on the treatment of atopic dermatitis in pediatric populations. #eadvcongress investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We're presenting data from our #dermatology portfolio at the 2023 Symposium on Hidradenitis Suppurativa Advances. Learn more at: investor.incyte.com/news-releases/news-release-details/da…. #shsa2023
-
Incyte
@Incyte
Today, Incyte launched #momentsofclarity in partnership with @TheMandyMoore, an initiative highlighting real stories of people living with mild to moderate #atopicdermatitis and their treatment journey. Learn more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
News: Today, we announced data focused on treatment options for patients living with vitiligo. #eadvcongress investor.incyte.com/news-releases/news-release-details/ne…
-
Incyte
@Incyte
Today, we announced the results of the 52-week data for a potential oral treatment option for people living with non-segmental vitiligo. #eadvcongress investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re looking forward to discussing and learning more about the latest advances in dermatology at #eadvcongress. Check out what we’re most excited to share at @EADV! investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We're honored to be recognized by @FOEWPHL as a 2023 Champion of Board Diversity with women making up more than 30% of our leadership board. Learn more. cdn.ymaws.com/foew.com/resource/resmgr/press_releases/202… #incyteproud #solveon
-
Incyte
@Incyte
October is #eczemaawarenessmonth! Hear more from Wendy Smith-Begolka, Senior VP of Scientific and Clinical Affairs of @NationalEczema, as she discusses key findings from the Patient-Focused Drug Development (PFDD) meeting. Learn more at startfromscratch.com. #eam #solveon
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
For each rare cancer, there are less than 40,000 people in the U.S. diagnosed per year. This #rarecancerday, we share our support for this community and our commitment to #solveon for patients.
-
Incyte
@Incyte
#news: Data from our #dermatology portfolio will be presented at the 2023 European Academy of Dermatology and Venereology #eadvcongress. Learn more about the research being featured at @EADV.
-
Incyte
@Incyte
September 15 marked the beginning of Hispanic & Latinx Heritage Month, a time for us to recognize, honor and reflect on the great influence Hispanic & Latinx Americans have on our society. Hear from our colleagues on what this month means to them.
-
Incyte
@Incyte
What is Chronic Myeloid Leukemia (CML)? We’re breaking it down to help put a spotlight on CML. #solveonforbloodcancer #worldcmlday #beleukemiaaware
-
Incyte
@Incyte
When it comes to graft-versus-host disease (GVHD), it’s important to know that individuals living with GVHD are not alone. Hear from @MiaHamm about the value of having fans to lean on. This #worldmarrowdonorday, learn more about the symptoms of GVHD.
-
Incyte
@Incyte
We’re excited to begin recruiting for Incyte’s postdoctoral fellowship programs in partnership with Saint Joseph’s University (@saintjosephs). We’re proud to offer these programs to help cultivate professional growth and Solve On.
-
Incyte
@Incyte
It’s #worldlymphomaawarenessday. #dyk diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in adults? Read on to learn more about DLBCL. #solveonstories #bloodcancerawarenessmonth #solveonforbloodcancer
-
Incyte
@Incyte
Nurse Mo (@StraightANurse) lives with a myeloproliferative neoplasm (MPN). As a dedicated healthcare professional, she knows firsthand how important it is to track your symptoms. Learn more. #mpnawarenessday #solveonforbloodcancer
-
Incyte
@Incyte
Over 437,000 people are diagnosed with leukemia each year. September 4 is #worldleukemiaday and a reminder to be aware of the symptoms of #leukemia. #beleukemiaaware #wld23
-
Incyte
@Incyte
September is #bloodcancerawarenessmonth and our commitment to #solveonforbloodcancer is stronger than ever. #solveon
-
Incyte
@Incyte
We #solveonforvitiligo because we see a better future for patients.
Read more about this year's Incyte Ingenuity Awards in vitiligo. -
Incyte
@Incyte
We’ve reported our Q2 2023 financial results and provided updates on key clinical programs. Learn more. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We’ve announced a clinical trial collaboration and supply agreement with @Replimune to evaluate a potential combination for patients with cutaneous squamous cell carcinoma.
-
Incyte
@Incyte
#news: We’ve announced with @Syndax positive topline results from the Phase 2 AGAVE-201 trial of axatilimab in patients with refractory chronic graft-versus-host disease (#gvhd). investor.incyte.com/news-releases/news-release-details/sy…
-
Incyte
@Incyte
We're #incyteproud to be recognized by @AmerChemSociety as one of the 2023 #heroesofchemistry for developing the first treatment for certain myeloproliferative neoplasms (#mpns), a group of rare blood cancers, and acute and chronic graft-versus-host disease (#gvhd).
-
Incyte
@Incyte
Targeted therapies can help inform management plans for rare cancers like cholangiocarcinoma (CCA). Read @NextAvenue's article about CCA and the tools care teams are using to improve patients' healthcare journeys.
-
Incyte
@Incyte
Patients inspire our scientists to #solveonforvitiligo. Hear more from Leonard about his experience living with #vitiligo. #solveonstories #vitiligoawarenessmonth
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Congratulations to the winners of the Incyte Ingenuity Awards in vitiligo, the American Academy of Dermatology (@AADSkin) & VStrong Vitiligo Support Community (@vstrong_detroit)! Applications for the 2023 IIA in vitiligo program are now open. #worldvitiligoday #solveonforvitiligo
-
Incyte
@Incyte
Today on #worldvitiligoday, we recognize the 70 million people across the world who have vitiligo.
Our employees share what drives their work to support this community. #solveonforvitiligo #vitiligoawarenessmonthThis media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Learn more about vitiligo by getting started with the basics about the condition. Join us in raising awareness this #vitiligoawarenessmonth. #solveonforvitiligo
-
Incyte
@Incyte
At Incyte, we recognize Juneteenth as a company holiday and honor its significance.
-
Incyte
@Incyte
Living with #vitiligo can be difficult, but hearing different perspectives may help. Learn more at thisisvitiligo.com.
-
Incyte
@Incyte
Tune in this weekend to see data from our oncology portfolio featured at the European Hematology Association 2023 (@EHA_Hematology) Hybrid Congress. #eha2023
-
Incyte
@Incyte
This week, we welcome Pablo J. Cagnoni, M.D., our new Head of Research & Development (R&D). Dr. Cagnoni will lead Incyte’s R&D efforts across our portfolio of programs in Oncology and Inflammation & Autoimmunity.
-
Incyte
@Incyte
We strive every day to create an environment where our employees are free to express themselves. This #pridemonth, join us in celebrating and supporting the LGBTQIA+ community. 🏳️🌈 #incyteproud
-
Incyte
@Incyte
We're thrilled to be recognized in the inaugural Global @Newsweek Top 100 Most Loved Workplace list. This is a testament to the value we place on creating a collaborative and inclusive working environment focused on innovation. #wesolveon #incyteproud
-
Incyte
@Incyte
Today, on #nationalcancersurvivorsday, we honor, support and remember those who have been impacted by cancer. The continued needs of the cancer community motivate us to work each day to discover new treatment options that could save the lives of patients.
-
Incyte
@Incyte
It’s #vitiligoawarenessmonth. Learn more about this autoimmune condition and help spread awareness by educating others. #solveonforvitiligo
-
Incyte
@Incyte
Every 27 seconds someone is diagnosed with a blood cancer. In honor of #worldbloodcancerday, listen to Jessica’s story about living with a rare blood cancer or myeloproliferative neoplasm (#mpn).
-
Incyte
@Incyte
We’re #incyteproud to be named to @USATODAY’s inaugural America’s Climate Leaders list! We’re committed to operating our business in a sustainable way. See the full list. www.usatoday.com/in-depth/news/nation/2023/05/24/climate-…
-
Incyte
@Incyte
Last night, we celebrated two of our inspiring colleagues at the 2023 @HBAnet Woman of the Year ceremony! Congrats to Valacia Titus and Axelle Magne De La Croix for receiving the HBA Rising Star awards! #hbaimpact #hbawoty23
-
Incyte
@Incyte
This #skincancerawarenessmonth we aim to #sharethefacts on Merkel Cell Carcinoma (#mcc), a rare skin cancer. Learn more about MCC and other skin cancers from @SkinCancerOrg.
-
Incyte
@Incyte
Congratulations to our CEO, @iloveincyte, who was named one of @FiercePharma’s Most Influential People in Biopharma! 👏 #incyteproud
-
Incyte
@Incyte
Despite progress, cancer continues to be a leading cause of death worldwide. At Incyte, we Solve On. for patients with cancer. #nationalcancerresearchmonth
-
Incyte
@Incyte
We’ve reported our Q1 2023 financial results and provided updates on key clinical programs. Learn more.
-
Incyte
@Incyte
#news: At the @RevAtopicDerm Conference, we’ve announced new results from the SCRATCH-AD trial evaluating our treatment for patients with mild-moderate #atopicdermatitis (AD), the most common type of eczema.
-
Incyte
@Incyte
At Incyte, innovation and inclusion are key to our culture. Today, we recognize #aapiheritagemonth and the significant contributions of the AAPI community.
-
Incyte
@Incyte
This #fopawarenessday marks the 17th anniversary of the discovery of the Fibrodysplasia Ossificans Progressiva (FOP) gene. At Incyte we are committed to #solveon for people with rare disorders, like FOP, by pursuing innovative research and raising awareness. Learn more about FOP.
-
Incyte
@Incyte
Happy #earthday! A more sustainable future is a priority at Incyte. Learn more about our ESG commitment and goals. #investinourplanet
-
Incyte
@Incyte
We are proud of the advances we have made for the dermatology community and are excited about the potential of our latest approval to help more eligible patients with vitiligo. Learn more.
-
Incyte
@Incyte
R&D is critical to our work at Incyte. Our Chief Scientific Officer, Dash Dhanak, recently joined other biopharma leaders for a Philly @BioBreakOrg panel to discuss R&D Innovation & Trends. Learn more about #biobreak's mission to bring the best of life sciences together. 🧑🔬
-
Incyte
@Incyte
This #worldhealthday, Steven Stein, Chief Medical Officer at Incyte, shares his perspective on the work Incyte is doing to advance scientific innovation and improve patient health. #healthforall
-
Incyte
@Incyte
Congratulations to Incyte’s Edimara Reis, Director, Antibody Pharmacology, for being selected as one of the 2023 Outstanding Delaware Women in STEM by @MillionWMentors Delaware! Edimara, your leadership and achievements serve as an inspiration to many. #incyteproud 🎉
-
Incyte
@Incyte
Incyte’s Valacia Titus and Axelle Magne De La Croix have received @HBAnet Rising Star awards for their outstanding contributions and commitment to excellence. Thank you both for your dedication to #solveon for patients! #hbaimpact
-
Incyte
@Incyte
It’s been an exciting weekend at #aad2023! Incyte’s Jim Lee, Group Vice President, Head of Inflammation and AutoImmunity, speaks about the data presented from our #dermatology portfolio.
-
Incyte
@Incyte
We’re at the @AADSkin Annual Meeting, where our research is being presented to thousands of professionals across the #dermatology community. Here’s a first look! #aad2023
-
Incyte
@Incyte
Learn more about our #dermatology portfolio and research being presented this weekend at @AADskin. #aad2023
-
Incyte
@Incyte
On #internationalwomensday, we celebrate the significant role and impact of women around the world. We are committed to supporting efforts to #embraceequity and foster an inclusive workplace. #iwd2023
-
Incyte
@Incyte
#news: We've announced a portfolio update. Read the press release to learn more: investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
It’s #employeeappreciationday 🥳 and we are thrilled to showcase our talented team working to make a positive impact for patients. Thank you for all that you do! #incyteproud
-
Incyte
@Incyte
This #rarediseaseday, we’re encouraging those living with rare, chronic blood cancers, like polycythemia vera (PV) to monitor and track their symptoms, which are, too often, hiding in plain sight. Learn more. #mpnshidinginplainsight #solveonforpatients
-
Incyte
@Incyte
Our purpose is to #solveonforpatients. We’re following the science and seeking to find new options for patients with unmet medical needs, including rare diseases. On #rarediseaseday, we share support for this community that is nearly 300 million strong!
-
Incyte
@Incyte
This #blackhistorymonth, we recognize Saint Elmo Brady, the first African American to earn a Ph.D. in chemistry. Dr. Brady went on to develop chemistry curriculums at HBCUs and mentored multiple generations of Black chemists. #bhm
-
Incyte
@Incyte
As we continue our celebration of #blackhistorymonth, we’re highlighting the important work of Jane Cooke Wright – a physician and pioneering researcher who dedicated 40 years to improving cancer treatment options for patients. #bhm
-
Incyte
@Incyte
As we work to #solveonforpatients, we honor and celebrate the critical role caregivers play in patients’ lives. Thank you, caregivers, for all that you do. #nationalcaregiversday
-
Incyte
@Incyte
#dyk: The incidence of cholangiocarcinoma (#cca), a rare and aggressive cancer, is increasing around the world. Join us in raising awareness of this #raredisease and how it impacts patients. #worldccaday #solveonforpatients
-
Incyte
@Incyte
We’re celebrating Black pioneers of science who have shaped the biopharma industry and today we highlight Percy Lavon Julian, a chemist and entrepreneur who discovered how to synthesize medicinal compounds from plants. #blackhistorymonth
-
Incyte
@Incyte
On International Day of Women and Girls in Science, we celebrate the many #womeninscience at Incyte who are helping to find meaningful solutions for patients. Two Incyte employees share what sparked their passion for working in science. #idwgis
-
Incyte
@Incyte
Kurt Brown, M.D., Incyte's Global Program Head Povorcitinib and Associate Vice President, Drug Development, Inflammation & AutoImmunity, shares his perspective on our new Phase 2 data in hidradenitis suppurativa and next steps for this potential treatment. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We’ve announced new 52-week data from our Phase 2 study evaluating a potential therapy for patients with hidradenitis suppurativa (#hs), a chronic and debilitating inflammatory skin condition. Learn more. #ehsf2023 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’ve reported our Q4 and year-end 2022 financial results and provided updates on key clinical programs.
-
Incyte
@Incyte
On #worldcancerday, Steven Stein, Chief Medical Officer at Incyte, discusses how Incyte’s R&D efforts in oncology strive to address unmet medical needs for patients. #solveonforpatients
-
Incyte
@Incyte
At Incyte, our science is driven by a purpose to Solve On. for patients. This month, we share our support for patients from the rare disease and oncology communities. Read more about our commitment to #solveonforpatients.
-
Incyte
@Incyte
There are many misconceptions about #vitiligo. To get the facts, check out #gettoknowvitiligo and learn more about this chronic immune-mediated skin condition.
-
Incyte
@Incyte
Meet Dija Atta, Senior Director of Clinical Operations at Incyte. Dija and her team work together to advance clinical development and improve the patient experience in clinical trials. #solveonstories #wesolveon
-
Incyte
@Incyte
Learn more about how the JAK-STAT pathway plays a key role in immune-mediated diseases in the latest #solveonstories.
-
Incyte
@Incyte
#vitiligo impacts individuals in different ways. Dermatologist, Dr. Pearl Grimes MD (@LAVitiligo), and patient advocates, Bryson and Mobola, discuss why speaking with your dermatologist is essential.
-
Incyte
@Incyte
For 20 years, we’ve had an unwavering dedication to science and making an impact for patients. Learn more about our growth, evolution and where we are headed on our new #solveonstories page.
-
Incyte
@Incyte
It’s Day 3 of #ash22. Check out the data from our #oncology portfolio, which will be presented today at the @ASH_hematology’s 64th Annual Meeting. #ash22
-
Incyte
@Incyte
It’s been an exciting few days at the @ASH_hematology 64th Annual Meeting! We look forward to sharing additional presentations from our #oncology portfolio. #solveon #ash22
-
Incyte
@Incyte
We’ve announced research (Abstract 6) at #ash22 on a new target, CALR, as we seek to expand treatment options for patients with myelofibrosis (MF) and essential thrombocythemia (ET). Learn more. @ASH_hematology #news
-
Incyte
@Incyte
Don’t miss these presentations today at Day 2 of #ash22. Tune in virtually or in-person to @ASH_hematology to learn more.
-
Incyte
@Incyte
We are onsite at the @ASH_hematology 64th Annual Meeting in New Orleans presenting our research to thousands of professionals in the hematology and oncology community including one of only six ASH plenary presentations. #ash22
-
Incyte
@Incyte
#news: We’ve announced data from our LIMBER clinical trials program, in which the goal is to advance science for patients living with myeloproliferative neoplasms (MPNs), at the @ASH_hematology’s 64th Annual Meeting. Learn more. #ash22 investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Today kicks off #ash22, and we will share a selection of data from across our #oncology portfolio. Tune in virtually or in-person to view key presentations at @ASH_hematology.
-
Incyte
@Incyte
Peter Langmuir, Vice President of Oncology Drug Development at Incyte, discusses what to expect from Incyte at #ash22. Follow along to learn more about our data and key presentations at the @ASH_hematology Annual Meeting.
-
Incyte
@Incyte
We’re excited to present research on our novel mutant CALR antibody at the @ASH_hematology Annual Meeting. Join us December 10-13 in New Orleans. #ash22
-
Incyte
@Incyte
#news: We’ve announced a Collaboration and License Agreement with CMS for ruxolitinib cream in Greater China and Southeast Asia investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
#news: We’ve announced a clinical trial collaboration and supply agreement with Mirati to evaluate INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We look forward to presenting data from our immuno-oncology portfolio at @sitcancer’s 37th Annual Meeting kicking off tomorrow. #sitc22
-
Incyte
@Incyte
#news: We are presenting more than 50 abstracts from our #oncology portfolio, including the Plenary Scientific Session at the @ASH_hematology Annual Meeting, December 10-13.
We’re proud of our science as we seek to meet patient needs. #ash22 -
Incyte
@Incyte
#news: we’ve reported our Q3 2022 financial results and updates on key clinical programs. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’re proud to be recognized by the @GalienFdn as a nominee for Best Pharmaceutical Agent at this year’s #prixgalien awards. Congratulations to this year’s winner and fellow nominees!
-
Incyte
@Incyte
We’re honored to have been named a 2022 Top Employer by @ScienceMagazine for the 5th consecutive year! Paula Swain, Executive Vice President, Human Resources, shares more about Incyte’s culture. #sctopemployer
-
Incyte
@Incyte
Exciting news! We are proud to share that for the fifth consecutive year, Incyte has been recognized as a Top Employer by @ScienceMagazine. #wesolveon
-
Incyte
@Incyte
"The more you know, the more powerful you are.” Listen to Chi Villines, #atopicdermatitis patient advocate & influencer, as she offers advice to individuals living with AD. To learn more and for AD resources, visit www.startfromscratch.com. #nationaleczemaawarenessmonth
-
Incyte
@Incyte
Incyte is seeking people over 18 years old with myelofibrosis (MF), a rare blood cancer, for two Phase 3 trials. Individuals currently on treatment or not on treatment may be eligible. Learn more about the trials and find out if you’re eligible.
-
Incyte
@Incyte
Understanding the science behind #atopicdermatitis can help you and your dermatologist better manage the condition. Learn more about the root cause of AD from Dr. Rebecca Smith, Board Certified Dermatologist, and visit www.startfromscratch.com. #nationaleczemaawarenessmonth
-
Incyte
@Incyte
Hear from David Rosmarin, MD, Vice Chair of Research and Education, Department of Dermatology at @TuftsMedicalCtr, as he shares his perspective on the @NEJM publication of the Phase 3 results from the TRuE-V clinical trial program in #vitiligo.
-
Incyte
@Incyte
We're excited to begin recruiting PharmD and PhD graduates for Incyte's postdoctoral fellowship program in partnership with Saint Joseph's University (@saintjosephs). We're proud to offer this program to cultivate professional growth.
-
Incyte
@Incyte
Paula Swain, our Executive Vice President of Human Resources, shares her perspective on Incyte being named a Top 100 Most Loved Workplace of 2022 by @Newsweek for the second year in a row. At Incyte, #wesolveon and it’s all made possible by our employees.
-
Incyte
@Incyte
We're thrilled to share that we've been recognized by @Newsweek as a Top 100 Most Loved Workplace for the second year in a row. Congratulations to our employees who foster a company culture built on collaboration, innovation and dedication to patients. #wesolveon #incyteproud
-
Incyte
@Incyte
At Incyte, we have always strived to support CML patients and caregivers. As of Oct. 3, CML Life, co-created by Incyte and @cmlnet has transitioned to CMLAN. We are thrilled that it will continue to provide support to the CML community under CMLAN’s leadership.
CML AdvocatesNetwork
@cmlnet
📣📣📢CML Life has a new home at CMLAN!
It is with great pleasure that we announce the expansion of our activities. CML Life is a unique support program that works to give patients and caregivers the support they need. Click here to learn more:
www.cmladvocates.net/.../cml-life-is-joining-the.../
#cmllife -
Incyte
@Incyte
#news: We’ve announced an agreement to acquire Villaris Therapeutics and auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Rare cancers can affect anyone, including the scientists who discover and develop treatments for them. On #rarecancerday, Sharon Diamond-Fosbenner reflects on how her daughter’s diagnosis brings perspective to her work at Incyte. #solveonforbloodcancer
-
Incyte
@Incyte
Congratulations to Incyte's Executive VP, Human Resources, Paula Swain, for receiving the Inaugural Star of Delaware Award at the @MakeAWishPHL's Celebration of Wishes event. The award recognizes leaders who have demonstrated steadfast, exemplary support to Make-A-Wish Delaware.
-
Incyte
@Incyte
At Incyte, our commitment to the blood cancer community extends well beyond #bloodcancerawarenessmonth in September. Hear more on how we #solveonforbloodcancer from Peg Squier, M.D., Ph.D., our Group Vice President of U.S. Medical Affairs. www.linkedin.com/pulse/incytes-commitment-solve-blood-can…
-
Incyte
@Incyte
This #worldcmlday we’re elevating conversations about chronic myeloid leukemia in partnership with @CMLNet. Learn more about #cml and what you can do to support the community by visiting cmladvocates.net. #solveonforbloodcancer #wcmld22
-
Incyte
@Incyte
Join us as we #solveonforbloodcancer and raise awareness of #lymphoma this #bloodcancerawarenessmonth. Learn more about this disease and its many subtypes through the Lymphoma Coalition (@knowyournodes). #wlad2022
-
Incyte
@Incyte
This #mpnawarenessday, we #solveonforbloodcancer for patients like Jessica and her son & caregiver, Jaden. Stay tuned for the Facebook event later this month to hear more about their experience living with myeloproliferative neoplasms (#mpns).
-
Incyte
@Incyte
We are looking forward to presenting data from our #dermatology portfolio at @EADV. Learn more about our dermatology research at #eadvcongress.
-
Incyte
@Incyte
September is #bloodcancerawarenessmonth. Follow us as we share stories of patients, their caregivers, and spotlight the incredible impact of our advocacy partners throughout the month as we #solveonforbloodcancer.
-
Incyte
@Incyte
We are thrilled to present data at @EADV from September 7-10. Learn more about our #dermatology portfolio being presented to the scientific community at #eadv2022 here: investor.incyte.com/news-releases/news-release-details/da…
-
Incyte
@Incyte
We’ve reported our Q2 2022 financial results and provided updates on key clinical programs.
-
Incyte
@Incyte
We’re thrilled to announce that we've been nominated by the @GalienFdn for Best Pharmaceutical Agent at the 2022 #prixgalien USA awards. Congratulations to all fellow nominees!
-
Incyte
@Incyte
What’s it like living with #vitiligo? Watch as Berardo shares his experience and his excitement for a new FDA-approved treatment option. incyte.com/dermatology
-
Incyte
@Incyte
Incyte has announced a new FDA-approved treatment for patients living with #vitiligo. David Rosmarin, MD, Vice Chair of Research and Education, Department of Dermatology at @TuftsMedicalCtr, discusses the importance of this milestone.
-
Incyte
@Incyte
Thank you @PHLBizJournal for naming us as a winner of the 2022 Healthiest Employers award. Our passions are our people and our science, and we are proud of the environment we’ve created at Incyte that greatly supports the health and wellness of our employees.
-
Incyte
@Incyte
Did you know nearly 70 million people across the world have #vitiligo? This #vitiligoawarenessmonth, we are raising awareness of this autoimmune condition in support of the vitiligo community.
-
Incyte
@Incyte
At Incyte, we are on a mission to change patients’ lives. While we are dedicated to supporting those in the vitiligo community every day, it is especially important to do so at key moments like #worldvitiligoday. Read more. www.linkedin.com/pulse/supporting-global-vitiligo-communi…
-
Incyte
@Incyte
#news: We’ve announced with @Novartis that the @EU_Commission has approved a new targeted therapy option for previously treated patients in Europe who are living with advanced non-small cell lung cancer (NSCLC). Learn more. cdn.incyte.com/Assets/european-commission-approval-of-tab…
-
Incyte
@Incyte
During #vitiligoawarenessmonth, we are encouraging more conversations around this serious autoimmune condition. Ahmad Naim, M.D., Vice President, U.S. Medical Affairs at Incyte, shares more about our commitment to supporting patients and the vitiligo community.
-
Incyte
@Incyte
We are proud that Incyte’s Hervé Hoppenot has been named a CEO of the Year by @DeBusinessTimes! Thank you for your leadership and dedication to making a difference by empowering our team to find solutions for patients with unmet medical needs.
-
Incyte
@Incyte
We will be presenting data from our #oncology portfolio at the @EHA_Hematology congress. #eha2022
-
Incyte
@Incyte
We look forward to showcasing data from our #oncology portfolio and partner programs at the #asco22 congress kicking off today. www.asco.org/annual-meeting
-
Incyte
@Incyte
This #worldbloodcancerday, join us in raising awareness for people living with various blood cancers. We are proud to continue to support the blood cancer community through our research and development efforts. #wbcd
-
Incyte
@Incyte
#news: Data from our #oncology portfolio will be presented to the scientific community at the @EHA_Hematology Congress. #eha2022 investor.incyte.com/news-releases/news-release-details/da…
-
Incyte
@Incyte
Cancer research is fundamental to our work at Incyte. This month, we recognize National Cancer Research Month and thank our world-class scientists for their commitment to finding solutions for the serious unmet medical needs of our patients. #ncrm22 #researchsaveslives
-
Incyte
@Incyte
#news: The @EU_Commission announced the approval of an Incyte-discovered therapy for the treatment of acute and chronic graft-versus-host disease (#gvhd). Read to learn more about the first approved post-steroid treatment for this disease. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We’ve announced our Q1 2022 financial results and provided updates on key clinical programs. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
At Incyte, we’re committed to minimizing our environmental impact. This #earthday, learn about our efforts to do our part to protect the environment with the help of our partnership with @NCX, the science-driven forest carbon marketplace. incyte.com/responsibility
-
Incyte
@Incyte
We’re attending the @RevAtopicDerm Annual Meeting to discuss treatment options for patients living with Atopic Dermatitis. #rad2022
-
Incyte
@Incyte
We are excited to celebrate the opening of a new facility at our headquarters to house our research and clinical development efforts. Thank you to our guest speakers for helping us celebrate this milestone.
-
Incyte
@Incyte
Since our founding, we’ve been working to improve the health of patients globally. This #worldhealthday, we reaffirm our commitment to #solveon for patients.
-
Incyte
@Incyte
#news: Today, we announced we have extended our support of the Incyte Cancer Care Assistance Fund for Delaware with @CancerSupportDE. Read the announcement to learn more.
-
Incyte
@Incyte
We’re proud to announce the opening of our new 1709 building in Wilmington, Delaware which will be home to over 440 Incyte employees and features additional state-of-the-art research facilities.
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
We are proud to announce that Puja Patel, Director, U.S. Product Strategy at Incyte has been named #mmm40under40 by @MMMnews. Thank you for your inspirational leadership and commitment to excellence.
www.mmm-online.com/40-under-40/40-under-40-puja-patel-inc… -
Incyte
@Incyte
At Incyte, we find innovative ways to improve the lives of patients. Our #dermatology team is dedicated to improving the lives of patients with immune-mediated dermatologic diseases. Join us at #aad2022 to learn more.
-
Incyte reposted
Eli Lilly and Company
@EliLillyandCo
Alopecia areata is an autoimmune disease that can cause devastating hair loss; there are no approved medicines. Learn about late-breaking clinical trial results for a potential treatment being studied for AA: e.lilly/3iEKNTQ #aad22
-
Incyte
@Incyte
Learn more about Incyte’s research and development work in #dermatology and presence at #aad2022 from Jim Lee, Incyte’s Group VP, Inflammation and Autoimmunity.
-
Incyte
@Incyte
We’re proud of Incyte’s Edimara Reis and Christine Lennon for receiving the @HBAnet Luminary and Rising Star awards for their inspirational leadership, valuable contributions, and commitment to excellence. Thank you both for all that you do! #hbaimpact
-
Incyte
@Incyte
#news: Data from our #dermatology portfolio will be presented to the scientific community at the @AADskin Annual Meeting on March 25-29. #aad2022
-
Incyte
@Incyte
News: We've announced the FDA has extended the sNDA review period for our treatment for vitiligo.
investor.incyte.com/press-releases/press-releases/2022/In… -
Incyte
@Incyte
We are a dedicated team committed to improving the lives of patients. This #employeeappreciationday, we express our deepest gratitude to our Incyte colleagues for their relentless hard work and dedication to advancing science. #teamincyte
-
Incyte
@Incyte
At Incyte, we are committed to making a meaningful difference in the lives of people living with rare diseases, like autoimmune hemolytic anemia (AIHA) as well as rare cancers. Learn more about how we Solve On. for patients this #rarediseaseday.
-
Incyte
@Incyte
In honor of #cholangiocarcinoma (#cca) Awareness Month, learn more about the importance of biomarker testing through these interviews with key experts in the space at @GoHealio.
-
Incyte
@Incyte
Thousands of people around the world develop #cholangiocarcinoma (#cca) each year. As a science-driven and patient-focused company, we aim to make a difference for CCA patients every day. #worldccaday
-
Incyte
@Incyte
February is #blackhistorymonth. At Incyte, we value diversity in backgrounds and perspectives. We are committed to promoting a collaborative, innovative, and inclusive work environment at which everyone can contribute to their fullest potential. #bhm
-
Incyte
@Incyte
We’ve reported 2021 Q4 and year-end financial results & provided updates on key clinical programs.
-
Incyte
@Incyte
This #worldcancerday and every day, we are committed to finding solutions for patients living with cancer. Learn more about our work in oncology.
-
Incyte
@Incyte
Rigorous science is at the core of everything we do to discover, develop, and commercialize novel medicines. In 2022, we will continue to explore and advance dermatology, oncology, and other programs to give back and benefit patient communities. Watch to learn more.
-
Incyte
@Incyte
Ahmad Naim, Vice President of US Medical Affairs, discusses the importance of recognizing #vitiligo as an immune-mediated skin condition. Read his blog article to find out more. www.linkedin.com/pulse/vitiligo-inflammatory-skin-conditi…
-
Incyte
@Incyte
Founded in 2002, Incyte has dedicated nearly 20 years to creating innovative medicines in oncology and dermatology for patients. Looking ahead to 2022, we will continue our pursuit to Solve On.
-
Incyte
@Incyte
It’s Day 3 of #ash21. Data from our #oncology portfolio will be presented today at the @ASH_hematology Annual Meeting and Exposition.
-
Incyte
@Incyte
Don’t miss these presentations today at #ash21. Tune in virtually or in-person to @ASH_hematology to view the presentations daily.
-
Incyte
@Incyte
#news: Data from the RE-MIND2 study in relapsed or refractory diffuse large B-cell lymphoma is being presented at the @ASH_hematology. #ash21
-
Incyte
@Incyte
As part of our commitment to patients with #atopicdermatitis, we strive to strengthen the relationship between patients and their dermatologists by providing tools to foster conversations. Learn more about the science behind #ad & access available resources at Start from Scratch.
-
Incyte
@Incyte
The @NCCN has updated its clinical guidelines for graft-versus-host disease (GVHD) to designate one of our approved therapies as a category 1 agent. www.nccn.org/home/news/ebulletindetail?EbulletinId=4131
-
Incyte
@Incyte
Our first Cryogenic Electron Microscopy (cryoEM) machine is advancing drug discovery research and helping us find solutions for patients with serious unmet medical needs through innovative technology.
-
Incyte
@Incyte
We’re excited to announce the opening of our BioPlant in Yverdon, Switzerland. This milestone underscores our investment in strong science and our commitment to finding innovative solutions that positively impact patients’ lives.
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
We’re pleased to present to the #oncology community, health care professionals & industry partners at the @SITCancer congress. Join us at #sitc21 to learn more about our data presentations. www.sitcancer.org/home
-
Incyte
@Incyte
#news: We’re recruiting for our new postdoctoral fellowship program in partnership with @USciences. At Incyte, we’re committed to the relentless pursuit of science and are proud to offer this program to PharmD and PhD graduates to cultivate professional growth and Solve On.
-
Incyte
@Incyte
#news: We will be presenting data from our #oncology portfolio to the scientific community at @ASH_hematology. Join us from December 11-14. #ash21
-
Incyte
@Incyte
We’ve reported our Q3 2021 financial results & provided updates on key clinical programs. investor.incyte.com/press-releases/press-releases/2021/In…
-
Incyte
@Incyte
#news: Data from our oncology portfolio will be presented at the @sitcancer congress. Learn more. #sitc21 investor.incyte.com/press-releases/press-releases/2021/Da…
-
Incyte
@Incyte
#news: The FDA has accepted a new drug application for our potential treatment for three types of relapsed or refractory non-Hodgkin lymphomas. investor.incyte.com/press-releases/press-releases/2021/In…
-
Incyte
@Incyte
Hervé Hoppenot, Chief Executive Officer at Incyte shares his excitement on being recognized as a top employer of 2021 by @ScienceMagazine. #sctopemployers www.science.org/content/article/2021-s-top-employers-enga…
-
Incyte
@Incyte
In light of our recent recognition as a top employer of 2021 by @ScienceMagazine, hear more from Julie Bekaert, Senior Medical Director of Hematology, Incyte Europe, about our employees’ positive impact on patients’ lives. www.science.org/content/article/2021-s-top-employers-enga…
-
Incyte
@Incyte
We’ve been recognized by the @GalienFdn as a nominee for Best Pharmaceutical Agent at the #prixgalien awards. Congratulations to this year’s winner & other fellow nominees.
-
Incyte
@Incyte
Incyte has been recognized as a top employer of 2021 by @ScienceMagazine. This recognition exemplifies our employees’ commitment to our science, innovation, and patients to help Solve On. www.science.org/content/article/2021-s-top-employers-enga…
-
Incyte
@Incyte
Incyte promotes a company culture where our colleagues feel fulfilled and valued. Eiji Ueda, Executive Director, Head of Clinical Development, Incyte Japan describes his experience working at Incyte in three words.
-
Incyte
@Incyte
#news: @EMA_News has validated the MAA for our investigational treatment for adults & adolescents 12 years & older with #vitiligo. investor.incyte.com/press-releases/press-releases/2021/In…
-
Incyte
@Incyte
Hear more from Josh Hummel, our Senior Research Investigator of Chemistry about the commitment of our talented team and how that enables us to go the extra mile for our patients to achieve success as a company and for our employees.
-
Incyte
@Incyte
Incyte's recent recognition as one of America’s Most Loved Workplaces of 2021 by @Newsweek is driven by our belief in fostering a company culture that is built on collaboration & innovation. Hear more from some of our employees. www.newsweek.com/americas-most-loved-workplaces-2021
-
Incyte
@Incyte
Incyte has been named as one of the Top 100 Most Loved Workplaces of 2021 by @Newsweek. We are thankful for our employees’ collaboration & commitment to patient-focused innovation. cdn.incyte.com/Assets/Incyte_NewsweekMostLovedWorkplaces_…
-
Incyte
@Incyte
#atopicdermatitis (#eczema) affects 31.6 million people in the US. This #nationaleczemaawarenessmonth, encourage someone living with AD to be proactive and make an appointment with a dermatologist who can help them understand their condition. #geteczemawise
-
Incyte
@Incyte
We’re proud of Incyte’s Paula Swain, Executive Vice President of Human Resources, for receiving @PHLBizJournal’s Women of Distinction award for her outstanding achievements, inspirational leadership and commitment to excellence. Thank you for all you do to serve our team!
-
Incyte
@Incyte
Incyte’s Group VP, Business Unit Head, Inflammation and Autoimmunity, Todd Edwards shares his perspective on what #nationaleczemaawarenessmonth means to Incyte and our steadfast commitment to advancing care for people with #atopicdermatitis (#eczema). www.linkedin.com/pulse/recognizing-national-eczema-awaren…
-
Incyte
@Incyte
Did you know there are complex scientific processes causing the itch associated with #atopicdermatitis (#eczema)? This #nationaleczemaawarenessmonth, we remain committed to addressing unmet needs and supporting this community.
-
Incyte
@Incyte
#news: We’ve announced new data from our positive Phase 3 TRuE-V program in patients with #vitiligo, which is being featured in a late-breaking session at the #eadvcongress. #eadv2021 investor.incyte.com/press-releases/press-releases/2021/In…
-
Incyte
@Incyte
Tomorrow at the #eadvcongress, we are presenting data from our Phase 3 TRuE-AD program in patients with #atopicdermatitis (#eczema). Learn more. www.eadvcongress2021.org/index.php/home/scientific/scient…
-
Incyte
@Incyte
We are presenting key data from our #dermatology portfolio at the #eadvcongress. Learn more about our accepted posters. www.eadvcongress2021.org/index.php/home/scientific/scient…
-
Incyte
@Incyte
Incyte has been recognized again by @PHLBizJournal as one of the fastest-growing companies in Philadelphia. #soaring76 www.bizjournals.com/philadelphia/news/2021/09/23/soaring-…
-
Incyte
@Incyte
#news: We’ve announced a global collaboration and license agreement with Syndax to develop a potential treatment for patients living with chronic graft-versus-host disease (#gvhd) and other fibrotic diseases. investor.incyte.com/press-releases/press-releases/2021/Sy…
-
Incyte
@Incyte
Hervé Hoppenot, CEO of Incyte shares his perspective on this week's monumental milestone for our recently launched Incyte Dermatology franchise.
-
Incyte
@Incyte
Incyte has recently announced the launch of its dedicated #dermatology franchise. Today, Incyte Dermatology marks its first approval milestone as we continue to Solve On. in our commitment to the relentless research of science to improve the lives of patients.
-
Incyte
@Incyte
This #wcmlday21, we are supporting @cmlnet in bringing the chronic myeloid leukemia (#cml) global community together to raise awareness of the challenges patients are facing and show our commitment to improving patient care. Learn more. www.cml-life.com
-
Incyte
@Incyte
The FDA approval of Incyte's new innovative therapy provides an important new treatment option for certain patients with mild to moderate #atopicdermatitis.
-
Incyte
@Incyte
#breaking: The @US_FDA has approved our new innovative therapy for certain patients with mild to moderate #atopicdermatitis, the most common type of #eczema.
-
Incyte
@Incyte
Check out this blog post written by Peter Langmuir, Group Vice President, Oncology Targeted Therapeutics, that highlights the key challenges of diagnosing and managing cholangiocarcinoma (#cca) with an expert panel from our partnership with @GoHealio. www.linkedin.com/pulse/bridging-gap-between-patients-doct…
-
Incyte
@Incyte
#news: Data from our dermatology portfolio on #vitiligo and #atopicdermatitis (#eczema) will be presented at the #eadvcongress. Learn more. #eadv2021 investor.incyte.com/press-releases/press-releases/2021/In…
-
Incyte
@Incyte
This #bloodcancerawarenessmonth we reaffirm our commitment to Solve On. Join us in raising awareness for those affected by blood cancers worldwide.
-
Incyte
@Incyte
We’re pleased to join the eczema community, health care professionals & industry partners at the @nationaleczema Virtual #eczemaexpo. Visit our virtual booth to learn more about how we’re supporting people with dermatologic conditions.
-
Incyte
@Incyte
#news: The @EU_Commission has granted conditional approval of a new treatment for adults with relapsed or refractory diffuse large B-cell #lymphoma (#dlbcl) non-transplant eligible (NTE).
-
Incyte
@Incyte
We’ve reported our Q2 2021 financial results & provided updates on key clinical programs.
-
Incyte
@Incyte
We’ve announced an update on the status of our BLA for a treatment for certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).
-
Incyte
@Incyte
Check out key presentations on cholangiocarcinoma (#cca) at the @GoHealio virtual panel discussion focusing on the current landscape of genomic alterations and biomarker testing. www.healio.com/hematology-oncology/education-lab/2020/10_…
-
Incyte
@Incyte
Rigorous science is at the core of everything we do. Thank you @PhilaPACT for acknowledging our commitment to innovation and finding solutions for patients.
-
Incyte
@Incyte
We are dedicated to making a difference for those living with a #raredisease. Thank you @RareDiseases for naming Incyte as one of the #rareimpact honorees for our approved therapy for patients with #cholangiocarcinoma.
-
Incyte
@Incyte
This #worldvitiligoday, hear from Barbara on what it’s like to live with #vitiligo and why it’s critical to advance science for people living with this immune-mediated condition.
-
Incyte
@Incyte
We’ve announced the outcome of the FDA Oncologic Drugs Advisory Committee (ODAC) meeting reviewing our BLA in squamous cell carcinoma of the anal canal (SCAC).
-
Incyte
@Incyte
As a company committed to the relentless pursuit of science that can make a difference in healthcare, we are honored to have been named as one of the 2021 Healthiest Employers by @PHLBizJournal.
-
Incyte
@Incyte
Did you know that #vitiligo affects 1.5-3 million people in the U.S.? This #vitiligoawarenessmonth we are joining with the community to spread awareness of this immune-mediated condition.
-
Incyte
@Incyte
#news: Data from our #dermatology portfolio on #atopicdermatitis (#eczema) will be presented to the scientific community at the upcoming @RevAtopicDerm Virtual Conference.
-
Incyte
@Incyte
News: We've announced the FDA has extended the NDA review period for our treatment for atopic dermatitis, a type of eczema.
-
Incyte
@Incyte
Incyte CEO Hervé Hoppenot will be presenting at the Biopharma CEO Investor Forum tomorrow, June 7. We look forward to being a part of the long-term #sustainability conversation! #cifbiopharma @CECPTweets
-
Incyte
@Incyte
At #asco21, we will be presenting FIGHT-202 study updates highlighting one of our approved therapies for previously treated locally advanced/metastatic #cholangiocarcinoma.
-
Incyte
@Incyte
#news: We will be presenting data from our #oncology portfolio at the 2021 @EHA_Hematology Virtual Congress. Learn more. #eha2021
-
Incyte
@Incyte
#news: We’ve announced with our partners at @MorphoSys that the first patient has been treated in a Phase 3 study for patients newly diagnosed with diffuse large B-cell lymphoma (#dlbcl).
-
Incyte
@Incyte
We’ve been recognized by @FortuneMagazine and @ideapharma as one of the top five most innovative and inventive pharmaceutical companies of 2021.
-
Incyte
@Incyte
We’ve reported our Q1 2021 financial results & provided updates on key clinical programs.
-
Incyte
@Incyte
Data presentations highlighting an investigational therapy for patients with #atopicdermatitis, a type of #eczema, being presented at the 2021 Society for Investigative Dermatology virtual meeting. #sid2021
-
Incyte
@Incyte
#news: Data from our #dermatology portfolio on #atopicdermatitis (#eczema) will be presented to the scientific community at the Society for Investigative Dermatology Virtual Meeting. Learn more.
-
Incyte
@Incyte
Keep an eye out for key data from our clinical trial program in patients with #vitiligo being presented at #aadvmx2021 this weekend.
-
Incyte
@Incyte
Hear Brittany’s perspective on the impact #atopicdermatitis, a type of #eczema, can have on daily life and the importance of progressing science for people living with this dermatologic condition.
-
Incyte
@Incyte
Check out key presentations on data from our Phase 3 TRuE-AD program in patients with #atopicdermatitis (#eczema) being featured this weekend at the #aadvmx2021 virtual congress.
-
Incyte
@Incyte
David Rosmarin, M.D., Vice President of Research and Education, Dermatology Department at @TuftsMedicalCtr, explains the impact #vitiligo can have on patients and speaks to the importance of the data being presented at #aadvmx2021. Learn more.
-
Incyte
@Incyte
#news: We’ve announced new findings from our randomized Phase 2 study in patients with #vitiligo. #aadvmx2021
-
Incyte
@Incyte
#news: We’ve announced new findings from pooled analyses of our Phase 3 TRuE-AD program in patients with #atopicdermatitis (#eczema). #aadvmx2021
-
Incyte
@Incyte
Our research in #dermatology is focused on addressing the needs of people with immune-mediated dermatologic conditions, including #vitiligo, a chronic autoimmune disease. Learn about the prevalence of vitiligo and when symptoms typically appear. #aadvmx2021
-
Incyte
@Incyte
Steven Stein, M.D., Chief Medical Officer, speaks to how our discovery expertise in immunology forms the basis of our company, enabling Incyte’s work in dermatology. Learn about the research from our #dermatology portfolio that will be shared this weekend at #aadvmx2021.
-
Incyte
@Incyte
#aadvmx2021 will feature data from our #dermatology portfolio, including research on #vitiligo. Learn more about this dermatologic condition.
-
Incyte
@Incyte
#atopicdermatitis (#eczema) affects more than 30 million individuals in the U.S. Follow along at #aadvmx2021 to learn more about data being shared to address the needs of people with this disease.
-
Incyte
@Incyte
Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, shares his perspective on our research and development work in #dermatology. Follow along to learn more about our efforts and data being presented at the upcoming #aadvmx2021 congress. (1/5)
Incyte
@Incyte
At Incyte, our science-first approach forms the foundation of our company. Over the years, we’ve developed a deep understanding of #immunology, allowing us to unlock insights into processes associated with dermatologic diseases. (2/5)
Post not available here, view on X
Incyte
@Incyte
Our current dermatologic focus areas include #atopicdermatitis (#eczema), #vitiligo and #hidradenitissuppurativa (HS). For many patients, these conditions can profoundly impact daily life. (4/5)
Incyte
@Incyte
We’re excited to be participating in #aadvmx2021 to share more about our research in #dermatology as we strive to advance the science on behalf of patients living with serious dermatologic conditions. (5/5)
-
Incyte
@Incyte
#news: Multiple abstracts highlighting data from our #dermatology portfolio will be presented at #aadvmx2021. Follow along to learn more.
-
Incyte reposted
Eli Lilly and Company
@EliLillyandCo
JUST IN: An update about our randomized, placebo-controlled trial studying a Lilly medicine as a potential #covid19 treatment for hospitalized patients. Learn more: e.lilly/3dN4Mwz
-
Incyte
@Incyte
Our scientists led the development of the @CD_AACR manuscript, which shares their work with the genomic profile of FGFR2 fusions/rearrangements, further advancing treatment options and clinical understanding for #cholangiocarcinoma.
-
Incyte
@Incyte
#news: The @EU_Commission has granted approval for a new treatment for adults with locally advanced or metastatic #cholangiocarcinoma with FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
-
Incyte
@Incyte
We’re proud of Incyte’s Pam Politis and Jennifer Heckman for receiving the HBA Luminary and Rising Star awards for their outstanding achievements, inspirational leadership and commitment to excellence. Thank you both for all you do to serve our mission and team! #hbaimpact
-
Incyte
@Incyte
Our expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates for patients with cancers, including rare cancers. Learn about how we Solve On. for patients this #rarediseaseday.
-
Incyte reposted
National Organization for Rare Disorders (NORD)
@RareDiseases
NORD is proud to announce this year's rare heroes -- the 2021 #rareimpact Award honorees. Read the press release on our blog: rarediseases.org/nord-announces-this-years-heroes-of-rare… (1/3)
-
Incyte
@Incyte
#news: The @EMA_News has validated the Marketing Authorization Application (MAA) for our investigational therapy in adult patients with squamous cell anal #carcinoma (SCAC).
-
Incyte
@Incyte
#news: The @US_FDA has accepted for priority review the NDA for Incyte’s topical JAK inhibitor cream under development for #atopicdermatitis, a type of #eczema
-
Incyte
@Incyte
At Incyte, we develop treatments for cancers, including rare cancers like #cholangiocarcinoma. Through our unique discovery process, we continue to Solve On. for patients this #worldccaday.
-
Incyte
@Incyte
We’ve reported 2020 Q4 and year-end financial results & provided updates on key clinical programs.
-
Incyte
@Incyte
We’re dedicated to advancing science that can lead to innovative treatments. This #worldcancerday, we reaffirm our commitment to Solve On. and find solutions for patients living with cancer.
-
Incyte
@Incyte
#news: #chmp has issued a positive opinion on a treatment for adults with previously treated, unresectable, locally advanced or metastatic #cholangiocarcinoma. @EMA_News
-
Incyte
@Incyte
The new year brings new opportunity. Here’s what we accomplished in 2020… now, let’s see what 2021 brings!
-
Incyte
@Incyte
Our work in #dermatology is rooted in our expertise of the JAK-STAT pathway, implicated in a number of immune-mediated dermatologic conditions. Today, Incyte CEO Hervé Hoppenot, spoke about our dermatology portfolio at the 2021 Dermatology Summit.
-
Incyte
@Incyte
#news: We’ve announced a global development collaboration with Cellenkos to investigate a combination treatment for patients with #myelofibrosis (MF).
-
Incyte
@Incyte
#news: @NEJM published results from the @NIAIDNews sponsored ACTT-2 study of an Incyte-discovered medicine for certain patients hospitalized with #covid19.
-
Incyte
@Incyte
Day 3 of @ASH_hematology Virtual Meeting will feature an oral presentation on a therapy for patients with chronic-phase chronic myeloid leukemia (#cml). #ash20
-
Incyte
@Incyte
Key research results are being presented on chronic graft-versus-host disease (#cgvhd), a potential complication of stem cell transplants, at the @ASH_hematology Virtual Meeting. #ash20
-
Incyte
@Incyte
Data from the REACH3 trial showing an Incyte therapy significantly improved outcomes in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (#gvhd) will be presented at @ASH_hematology. #ash20
-
Incyte
@Incyte
Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity explains how we are using our cross-functional knowledge of JAK inhibition in our #dermatology efforts to address the needs of people with #immune-mediated dermatologic conditions.
-
Incyte
@Incyte
Our scientists are focused on transforming the treatment of #cancer and #inflammatory and #autoimmune conditions. Discover our molecules in development.
-
Incyte
@Incyte
#news: We’ve announced a global clinical collaboration with @MorphoSys and Xencor to investigate a combination treatment option for patients with diffuse large B-cell lymphoma (#dlbcl) and follicular #lymphoma (FL). investor.incyte.com/press-releases/press-releases/2020/Xe…
-
Incyte
@Incyte
We will be presenting data from our #oncology portfolio at the @sitcancer virtual meeting. #sitc2020
-
Incyte
@Incyte
We’ve reported 2020 Q3 financial results & provided updates on key clinical programs.
-
Incyte
@Incyte
#news: We will be presenting data from our #oncology portfolio to the scientific community at @ASH_hematology Virtual Meeting. #ash20
-
Incyte
@Incyte
Thank you @DeBusinessTimes for featuring perspective from Incyte’s Peg Squier, Group VP, US Medical Affairs, on how our teams come together to strive to make a global impact during times of crisis and beyond. delawarebusinesstimes.com/news/incyte-makes-global-impact/
-
Incyte
@Incyte
We’re honored to be listed as a #sctopemployer by @ScienceMagazine. Paula Swain, Executive VP, Human Resources, describes how this recognition underscores our commitment to being #science-driven, patient-focused which defines Incyte’s culture.
-
Incyte
@Incyte
We are proud to announce that we've been recognized as an #sctopemployer by @ScienceMagazine. We will continue our commitment to maintaining a strong culture & to the relentless pursuit of #science.
-
Incyte
@Incyte
We will have an encore presentation at the Society of Dermatology Physician Assistants (SDPA) Digital Conference and the Fall Clinical Dermatology Conference of our Phase 3 data for patients with #atopicdermatitis. Learn more at @dermPA and @fallclinical.
-
Incyte
@Incyte
#news: We’re presenting pooled data from our Phase 3 TRuE-AD program for patients with #atopicdermatitis at the 29th @eadv Virtual Congress. #eadv2020 #eadvvirtual
-
Incyte
@Incyte
We're at the 29th @eadv Virtual Congress sharing data from our #dermatology trials with the scientific community. #eadv2020 #eadvvirtual
-
Incyte
@Incyte
#atopicdermatitis affects more than 30 million individuals in the U.S. and is common in both adults and children. Learn more this #nationaleczemaawarenessmonth.
-
Incyte reposted
Eli Lilly and Company
@EliLillyandCo
New: Lilly and @Incyte are sharing additional data showing reduced time to recovery and improved clinical outcomes for patients with #covid19 infection requiring oxygen. Learn more: e.lilly/30OG4qe
-
Incyte
@Incyte
Join the @curecc Living with Cholangiocarcinoma – Journey to Diagnosis & Beyond Facebook Live event on Thursday at 7:00pm ET to engage in a discussion about survey results on the diagnostic journey & impact of #cholangiocarcinoma.
-
Incyte
@Incyte
October is #nationaleczemaawarenessmonth. We remain committed to addressing the unmet needs of those who have #atopicdermatitis. Learn about @nationaleczema's initiative & join us in raising awareness.
-
Incyte
@Incyte
At Incyte, we Solve On. Today and every day we continue to innovate to find new solutions for patients, including those with rare cancers. #rarecancerday
-
Incyte
@Incyte
This #rarecancerday, hear from patients with an MPN and #cca who share their stories and how they advocate for their health.
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
At Incyte, we follow the #science to find solutions for serious unmet medical needs. As we head into #rarecancerday, learn about our discovery efforts in #cholangiocarcinoma, a rare and aggressive cancer.
-
Incyte
@Incyte
As #rarecancerday approaches, learn more about our rare cancer pipeline and commitment to improving the lives of those living with rare cancers.
-
Incyte
@Incyte
We're thrilled to announce that we've been recognized on @PHLBizJournal's #soaring76 list as one of Philadelphia’s fastest-growing companies.
-
Incyte
@Incyte
At Incyte, we Solve On. In our work, there's no finish line.
-
Incyte
@Incyte
Take time today to learn more about chronic myeloid leukemia (#cml) and how you can support the community. CML Life offers resources dedicated to helping improve the lives of those affected by CML. #worldcmlday
-
Incyte
@Incyte
At our core, we are dedicated to finding solutions for patients impacted by cancer and inflammatory and autoimmune diseases.
-
Incyte
@Incyte
Incyte is honored to fund the implementation of @MassGeneralNews' innovative project for the betterment of the graft-versus-host disease (#gvhd) community.
-
Incyte
@Incyte
Incyte is committed to addressing the unmet needs of patients with #atopiceczema. Join us in advocating for these patients this #atopiceczemaday and every day.
-
Incyte
@Incyte
Myeloproliferative neoplasms (#mpns) are a group of rare, chronic blood cancers. Together, let's support the MPN community by raising awareness of these devastating diseases. #mpnawarenessday
-
Incyte
@Incyte
We’re honored to share that @american_skin1 has recognized our work in dermatology by selecting us as the recipient of the Global Impact Award in Biopharmaceutical Research and Medicine. Hear more from Jim Lee, Group Vice President and Head of Inflammation and Autoimmunity.
-
Incyte
@Incyte
We're proud to announce that @MassGeneralNews is the recipient of the 2020 Incyte Ingenuity Award. Their innovative idea shows a commitment to improving the lives of those affected by graft-versus-host disease (#gvhd).
-
Incyte
@Incyte
Approximately 30% of non-Hodgkin lymphoma (NHL) cases are #dlbcl. Please join us in raising continued awareness of this serious disease. #bloodcancerawarenessmonth #lymsm
-
Incyte
@Incyte
Today is #wld20! #leukemia is a type of cancer that affects white blood cells, the cells which typically fight infection. Find out more about @AcuteLeuk's initiative & help raise awareness.
-
Incyte
@Incyte
We're proud to recognize the myeloproliferative neoplasm community in honor of the 10th anniversary of #bloodcancerawarenessmonth, supporting activities that bring awareness to myeloproliferative neoplasms (#mpns).
-
Incyte
@Incyte
#breaking: @NEJM published pivotal results from the GEOMETRY mono-1 study of an Incyte-discovered therapy for patients with METex14 metastatic non-small cell #lungcancer (NSCLC).
-
Incyte
@Incyte
We Solve On. for the blood cancer community. This #bloodcancerawarenessmonth, we're reflecting on memorable milestones that have supported the blood cancer community over the years.
-
Incyte
@Incyte
Data from the Phase 3 REACH2 study evaluating our therapy for patients with steroid-refractory acute graft-versus-host disease (#gvhd) will be presented at @TheEBMT Annual Conference. #ebmt20virtual
-
Incyte
@Incyte
Our inflammation & autoimmunity (IAI) research team utilizes its cross-functional knowledge of our programs to discover, develop & deliver innovative approaches to treating immune-mediated diseases.
-
Incyte
@Incyte
The @NCCN has added our and @MorphoSys' approved therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (#dlbcl), who are not eligible for transplant, to its clinical guidelines.
-
Incyte
@Incyte
In collaboration with @MorphoSys, we are proud to offer a new targeted treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (#dlbcl).
-
Incyte
@Incyte
Incyte reports 2020 Q2 financial results & updates on key clinical programs. Read our press release.
-
Incyte
@Incyte
#breaking: Incyte and @MorphoSys announced that the @US_FDA has approved a new targeted treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (#dlbcl).
-
Incyte
@Incyte
We’re excited to share that an Incyte-discovered medicine has been nominated for the 2020 #prixgalien USA Awards from the @GalienFdn, which recognizes impactful 2020 global health innovation, in the Best Pharmaceutical Agent category.
-
Incyte
@Incyte
Cytokine storm is a severe immune overreaction that can be triggered by viral infection & can lead to serious complications. Learn more about how #covid19 related cytokine storm affects the lungs. incyte.com/covid-19
-
Incyte
@Incyte
We’re excited to participate in the first Virtual #eczemaexpo to support patients & raise awareness of #atopicdermatitis. @nationaleczema
-
Incyte
@Incyte
We are committed to supporting our patients, our colleagues & our business in a way that protects the environment & enhances the communities around us. Learn more about our Global Responsibility initiative.
-
Incyte
@Incyte
#news: @TheLancet has published data from a randomized, controlled study on our investigational treatment for patients with #vitiligo.
-
Incyte
@Incyte
We're thrilled to open our new European headquarters in the Swiss city of Morges. We are looking forward to the increased collaboration & innovation this building will foster.
-
Incyte
@Incyte
At Incyte, we take the health of our employees very seriously & we're thrilled to be recognized as a finalist by @PHLBizJournal for the 2020 Healthiest Employer award. www.bizjournals.com/philadelphia/news/2020/06/24/healthie…
-
Incyte
@Incyte
Kimberly Boyd sheds light on the need for #vitiligo patient support and why she advocates for the vitiligo community, as a patient and member of the @StepUp4Vitiligo team. #virtualworldvitiligodayusa
-
Incyte
@Incyte
Erika Page, Living Dappled Founder & Editor, was inspired to start her own advocacy organization to help uplift & educate others with #vitiligo. #vitiligoawarenessmonth
This media couldn't be displayed. See it on the original post. -
Incyte
@Incyte
Our Executive Vice President, General Manager, U.S., Barry Flannelly, provides an overview of the Incyte Ingenuity Award program, currently accepting applicants.
-
Incyte
@Incyte
We recognize the importance of building a sustainable business for the health and safety of our people, patients and communities.
-
Incyte
@Incyte
Join us starting today at @AADSkin’s Virtual Meeting Experience, where we’ll be sharing data from our Atopic Dermatitis and Vitiligo programs with the scientific community. #aadvmx2020
-
Incyte
@Incyte
We're presenting data from our Phase 2 study investigating the addition of PI3Kδ inhibition to JAK inhibition for patients with myelofibrosis. Visit @EHA_Hematology's library to review. #eha25virtual
-
Incyte
@Incyte
We're proud to share data around an investigational treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r #dlbcl) during the virtual 25th @EHA_Hematology Annual Congress, which kicks off today. #eha25virtual
-
Incyte
@Incyte
We're pleased to be a part of the virtual 25th @EHA_Hematology Annual Congress to continue sharing #oncology data with the scientific community. #eha25
-
Incyte
@Incyte
This World Blood Cancer Day, visit @VoicesofMPN to explore online patient tools and resources that can be accessed from your own home. #wbcd
-
Incyte
@Incyte
Data from our oncology portfolio will be presented virtually at the 2020 @ASCO Annual Meeting & the 25th Congress of @EHA_Hematology. Stay tuned! #asco20 #eha25
-
Incyte
@Incyte
#breaking: We’ve announced long-term results from the ongoing Phase 2 L-MIND study in relapsed or refractory diffuse large B-cell lymphoma with our partners @MorphoSys. Full efficacy & safety data will be presented virtually at the 25th @EHA_Hematology Annual Congress.
-
Incyte
@Incyte
We’re proud that another Incyte discovered treatment is being tested as a potential therapy for patients with #covid19. Read the details on the @NIAIDNews study.
-
Incyte
@Incyte
#breaking: We’ve announced with @Novartis that the @US_FDA has approved a new targeted treatment for patients with metastatic non-small cell #lungcancer.
-
Incyte
@Incyte
Incyte reports 2020 Q1 financial results & provides updates on key clinical programs. Read our press release.
-
Incyte
@Incyte
Learn more about the role of molecular profiling in helping doctors identify options for people with #cholangiocarcinoma.
-
Incyte
@Incyte
Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, shares what the recent FDA milestone means for adults with previously treated, unresectable locally advanced or metastatic #cholangiocarcinoma.
-
Incyte
@Incyte
#breaking: The @US_FDA has approved the first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic #cholangiocarcinoma.
-
Incyte
@Incyte
#breaking: We’re presenting data from our Phase 3 TRuE-AD program for an investigational treatment for patients with #atopicdermatitis at the Revolutionizing Atopic Dermatitis 2020 Virtual Symposium. @RevAtopicDerm
-
Incyte
@Incyte
Register for the Revolutionizing Atopic Dermatitis 2020 Virtual Symposium on Sunday, April 5th starting at 11:00 am ET, where data on our investigational therapy for patients with #atopicdermatitis will be shared via the live stream. @RevAtopicDerm
-
Incyte
@Incyte
#news: @TheLancet has published a Phase 2 study, evaluating our investigational treatment for adults with previously treated, locally advanced or metastatic #cholangiocarcinoma.
-
Incyte
@Incyte
#breaking: Our global collaboration and licensing agreement with @MorphoSys for the treatment of B cell malignancies has received antitrust clearance.
-
Incyte
@Incyte
We show support for the #raredisease community through our @VoicesOfMPN program that provides resources & a place to connect for those living with #mpns.
-
Incyte
@Incyte
J.G. Jones shares his #raredisease story for "Rare Reflections: MPNs Unmasked." Take a look and discover life living with an #mpn #rarediseaseday.
-
Incyte
@Incyte
We’re proud to share J.G.’s #mpn story. Learn more about Rare Reflections: MPNs Unmasked: www.voicesofmpn.com/mpn-blog
Voices of MPN
@VoicesofMPN
We’re thrilled to unveil “Rare Reflections: MPNs Unmasked,” a campaign with @Incyte that beautifully shines light on J.G. Jones’ journey living with an #mpn.
-
Incyte
@Incyte
Our inflammation & autoimmunity scientists are exploring JAK inhibition to potentially treat a number of immune-mediated diseases.
-
Incyte
@Incyte
The development of immune-mediated conditions is often from overactivation of the JAK pathway. Learn more about how our team of dedicated scientists are exploring the potential of JAK inhibition.
-
Incyte
@Incyte
#breaking: Our second Phase 3 TRuE-AD study met its primary and secondary endpoints in patients with #atopicdermatitis.
-
Incyte
@Incyte
We aim to identify & target pathways in our inflammation & autoimmunity group that leads to the destruction of the body's own cells & tissues, striving to restore normal immune function to bring the body closer to homeostasis.
-
Incyte
@Incyte
Incyte reports 2019 Q4 financial results & provides updates on key clinical programs. Read our press release.
-
Incyte
@Incyte
On this #worldccaday, we are proud to join organizations like @curecc to empower patients & caregivers affected by this disease. We recognize the HCPs who are aiding in the advancement of research. @WorldCCADay.
-
Incyte
@Incyte
On this #worldccaday, our colleague & Medical Director Oncology, Luis R. Féliz Viñas, weighs in on the power of partnership to raise awareness for cholangiocarcinoma patients. @CCA_Alliance.
-
Incyte
@Incyte
As #worldccaday approaches, join us in recognizing and supporting those affected by #cholangiocarcinoma.
WorldCCADay
@WorldCCADay
Let’s unite on February 12 –#worldccaday. Do you have your #cholangiocarcinoma graphics ready to share? Learn how you can get involved here👇👇 worldcholangiocarcinomaday.org
#bileductcancer #cancerawareness -
Incyte
@Incyte
#dyk that #cholangiocarcinoma is most common in those 65 years old and above? Learn the symptoms of this rare cancer ahead of #worldccaday
-
Incyte reposted
Novartis News
@NovartisNews
FDA granted Priority Review to investigational treatment for patients with a specific mutation in advanced non-small cell lung cancer. #novartisnews #nsclc
-
Incyte
@Incyte
Luis R. Féliz Viñas, Medical Director Oncology at Incyte, explains what #cholangiocarcinoma is & how personalized molecular profiling can help identify different treatment approaches. #worldccaday
-
Incyte
@Incyte
Join us in raising awareness for #worldccaday, where we join organizations globally to advocate and show support for people with #cholangiocarcinoma.
Cholangiocarcinoma Foundation
@curecc
#worldccaday is fast approaching; let the countdown begin! Become a part of the #cholangiocarcinoma
community to help raise awareness about this devastating disease! #bileductcancer #cancerawareness
worldcholangiocarcinomaday.org -
Incyte
@Incyte
#cholangiocarcinoma is often overlooked due to non-specific symptoms, which can lead to a late diagnosis. Hear from Incyte Chief Medical Officer, Steven Stein, about the importance of advancing research for this #raredisease. #worldccaday
-
Incyte
@Incyte
Learn more about what FGFR2 fusions or rearrangements mean for people with #cholangiocarcinoma. #worldccaday @WorldCCADay
-
Incyte
@Incyte
For Incyte, #worldccaday means recognizing the global efforts made to address the serious unmet need for people with #cholangiocarcinoma.
-
Incyte
@Incyte
Reflecting on #worldcancerday, we continue our commitment to take action against #cancer. Our team of researchers strives daily to create innovative medicines for patients in serious need. #iamandiwill
-
Incyte
@Incyte
#breaking: Our Phase 3 TRuE-AD2 study met its primary endpoint in patients with #atopicdermatitis.
-
Incyte
@Incyte
Our sense of purpose comes from the stories of our patients that we serve in the search for scientific discoveries.
-
Incyte
@Incyte
Join a team that has a unique entrepreneurial attitude, which drives their approach in the pursuit of scientific excellence.
-
Incyte
@Incyte
We continually modify our discovery efforts to maximize our findings when & where we need it so that each program, regardless of stage, is executed in the most efficient and data-rich manner possible.
-
Incyte
@Incyte
#breaking: Incyte & @MorphoSys announce a global collaboration & license agreement, including U.S. co-commercialization and Ex-U.S. commercialization rights for tafasitamab investor.incyte.com/news-releases/news-release-details/mo…
-
Incyte
@Incyte
Our strategy to discover immuno-oncology therapies is based on studying & understanding the diversity of cells required to maintain an immune-suppressive tumor microenvironment.
-
Incyte
@Incyte
Through trials & challenges, successes & failures, we keep going because scientific research is an obstacle course. We are committed to pushing through each challenge on behalf of our patients.
-
Incyte
@Incyte
Our goal for the inflammation & autoimmunity development group is to identify, target & modulate immunological pathways driving uncontrolled inflammation & the destruction of the body’s own cells and tissues.
-
Incyte
@Incyte
We're committed to finding solutions that don't yet exist for patients who are top of mind in all that we do. At Incyte, we Solve On.
-
Incyte
@Incyte
Discovery, development & delivery drove us in 2019. Now, we're ready to continue and Solve On in 2020. #happynewyear
-
Incyte
@Incyte
Check out our clinical trial resources to aid patients in making informed decisions.
-
Incyte
@Incyte
In the areas of inflammation & autoimmunity, we see potential to address the needs of patients with immune-mediated diseases & are developing potential new therapies that aim to positively impact patients' lives.
-
Incyte
@Incyte
Wishing everyone - from the patient & local communities we aim to serve, to our employees & industry partners - a joyful holiday season and prosperous New Year.
-
Incyte
@Incyte
Our discovery capabilities within the field of immunotherapy open distinct opportunities to target diverse mechanisms.
-
Incyte
@Incyte
Our dedicated researchers are focused on finding solutions for patients with cancer and immune-mediated diseases.
-
Incyte
@Incyte
What is one of the most rewarding aspects of #lifeatincyte according to our CEO? The possibility of having a positive impact on the lives of patients.
-
Incyte
@Incyte
Living with an #mpn can present many challenges. Find resources & more through @VoicesOfMPN.
-
Incyte
@Incyte
Since we were founded in 2002, our scientists strive to create innovative medicines for patients. Explore our areas of study & find out how to get involved:
-
Incyte
@Incyte
#sciencespotlight: Learn more about our development of an antagonistic anti-LAG-3 antibody and its relationship to #cancer.
-
Incyte
@Incyte
We're capitalizing on our immunology expertise to explore areas in which our research may have impactful applications in inflammation & autoimmunity.
-
Incyte
@Incyte
We believe in fostering a company culture that is built on collaboration & innovation to enable employees to grow to their full potential. #lifeatincyte
-
Incyte
@Incyte
Our commitment to the relentless pursuit of science drives our efforts to improve the lives of patients, make a difference in healthcare & build sustainable value for our communities. We are here to Solve On.
-
Incyte
@Incyte
Thank you to @cure_magazine for hosting the 2019 MPN Heroes at this year’s Recognition Ceremony. Always such an honor to be surrounded by so many who support, empower and acknowledge the #mpn community. #mpnsm
-
Incyte
@Incyte
We're excited to celebrate the 2019 MPN Heroes at tonight's Recognition Ceremony in collaboration with @cure_magazine. Learn more about the individuals who make a difference in the lives of those with MPNs.
-
Incyte
@Incyte
We are proud to share that our CEO, Hervé Hoppenot, has been recognized by the @PHLBizJournal as one of the Most Admired CEOs in 2019. His leadership guides our mission to support patients and the communities we serve.
-
Incyte
@Incyte
Since its creation in 2016, our Incyte Involved program has played an important role in our company's DNA. We're committed to making a difference in our communities.
-
Incyte
@Incyte
#sciencespotlight: We're utilizing our expertise of the JAK pathway to address unmet needs in inflammation & autoimmunity.
-
Incyte
@Incyte
#breakingnews: We will showcase data from our oncology portfolio at the 61st Annual #ash19.
-
Incyte
@Incyte
With our science-first approach, heritage in immunology and deep understanding of the JAK pathway, we aim to make a difference for patients.
-
Incyte
@Incyte
We're at the @KeyWestFilmFest where our short film "Beyond Blue" shows a glimpse inside Barbara's life living with an #mpn. We're proud to have created a film that supports the #raredisease community & raises awareness of MPNs. #kwff
-
Incyte
@Incyte
On the agenda at the Dermatology Drug Development Summit: Incyte Senior Director of Translational Research, Michael D. Howell, PhD, to present the integration of personalized medicine for #dermatology patients.
-
Incyte
@Incyte
Our immunotherapy research is based on the diversity of cells required to maintain an immune-suppressive microenvironment.
-
Incyte
@Incyte
Hear from our colleague & Research Fellow, Discovery Chemistry, Eddy Yue, on why he decided to pursue a career as a chemist. #lifeatincyte
-
Incyte
@Incyte
We're proud to screen our short film "Beyond Blue" which reveals Barbara's experiences living with an #mpn at the upcoming @KeyWestFilmFest #kwff
-
Incyte
@Incyte
We have the unique opportunity to make an impact within the Inflammation & Autoimmunity landscape due to our deep understanding of the JAK pathway.
-
Incyte
@Incyte
We aim to cultivate a work environment that inspires #discovery. Hear from Ankur Shah, Senior Director of U.S. Medical Information, on what makes #lifeatincyte rewarding.
-
Incyte
@Incyte
At our core, we believe the advancement of basic science fuels the discovery of innovative medicines for patients. Learn more about our approach to research.
-
Incyte
@Incyte
Our short film, "Beyond Blue", will be screened at the #disorder Film Festival. Watch here to learn more. #mpnsn youtu.be/peGlYI6J7HM
-
Incyte
@Incyte
Our core strength lies in the collective experiences and passion of our teams. Learn more about our team's opportunities.
-
Incyte
@Incyte
We’re proud to have been named a #sctopemployer again this year. Hear from our Head of HR, Paula Swain, on why we believe in work-life balance for all of our employees. #lifeatincyte
-
Incyte
@Incyte
We're proud to announce that our Head of Human Resources, Paula Swain, has won the @DeBusinessTimes 2019 HR Executive of the Year Award. Congratulations to her & all other nominees for their outstanding leadership. #womaninscience #dehrawards
-
Incyte
@Incyte
Knowing the ins and outs of #clinicaltrials can be crucial during the patient journey. Explore tools & resources available to make informed choices.
-
Incyte
@Incyte
We're developing a small molecule inhibitor of AXL & MER, which may have direct anti-tumor effects when in therapeutic form.
-
Incyte
@Incyte
Our Head of HR, Paula Swain, weighs in on our patient-focused mission and how we integrate this belief into our everyday work at Incyte. Watch to learn more. #lifeatincyte
-
Incyte
@Incyte
Our targeted therapy discovery strategy enables us to leverage cross-program knowledge in our R&D efforts. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
We recognize that with growth often comes change. While reflecting on our recent #sctopemployer recognition, our Head of HR, Paula Swain, shares how we strive to maintain the strong culture behind #lifeatincyte.
-
Incyte
@Incyte
To our Chief Scientific Officer, Dash Dhanak, #innovation means making a difference for patients. Watch to hear more. #lifeatincyte
-
Incyte
@Incyte
Incyte reports 2019 Q3 financial results & provides updates on key clinical programs. Read our press release.
-
Incyte
@Incyte
Our science extends beyond oncology to include the study of PI3Kδ inhibition across a variety of B-cell mediated & antibody-driven diseases.
-
Incyte
@Incyte
ICYMI: We’ve been recognized as a #sctopemployer by @ScienceCareers. Hear from our Head of HR, Paula Swain, on the top qualities that Incyte looks for when growing teams. #lifeatincyte
-
Incyte
@Incyte
We’re proud to share that our CEO, Hervé Hoppenot, has been recognized by @PHLBizJournal as one of the Top 25 Most Admired CEOs of 2019—an outstanding and well-deserved honor!
Philadelphia Business Journal
@PHLBizJournal
The 25 honorees were selected from nearly 100 nominations across a scope of industries. www.bizjournals.com/philadelphia/news/2019/10/16/philadel…
-
Incyte
@Incyte
Our Chief Scientific Officer, Dash Dhanak, shares his perspective on what it means for Incyte to be recognized as a #sctopemployer by @ScienceCareers. #lifeatincyte
-
Incyte
@Incyte
To Barry Flannelly, Executive Vice President, General Manager, U.S., #lifeatincyte offers the opportunity to discover, develop and deliver for patients. Hear more on what it means to be recognized as a #sctopemployer by @ScienceCareers.
-
Incyte
@Incyte
For our Head of HR, Paula Swain, our 2019 Top Employer recognition by @ScienceCareers truly reflects how Incyte employees feel about the company. Thank you to all who contribute to #lifeatincyte! #sctopemployer
-
Incyte
@Incyte
#breaking: We’re proud to announce that we’ve been named a Top Five Biopharma Employer by @ScienceCareers for the second year in a row! #sctopemployer
-
Incyte
@Incyte
Our colleagues are motivated by our rigorous pursuit of R&D excellence & encouraged to be creative while innovating for patients. #lifeatincyte
-
Incyte
@Incyte
Participants in #clinicaltrials contribute to the greater scientific understanding of their disease & the treatment being studied.
-
Incyte
@Incyte
Our R&D efforts related to inflammation & autoimmunity enable us to identify potential treatments that can bring the body closer to homeostasis.
-
Incyte
@Incyte
Our goal is not only to make a difference in the lives of patients but also to contribute to & support our local communities.
-
Incyte
@Incyte
#breaking at #eadv2019: We've announced results from our Phase 2 study evaluating a potential treatment for patients living with #vitiligo. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Clinical trials are a vital part of the discovery process as we look for new ways to improve health.
-
Incyte
@Incyte
Our colleagues are core to our discovery efforts & the foundation to maximizing the impact of our programs.
-
Incyte
@Incyte
Our Group VP & Head of Inflammation & Autoimmunity, Jim Lee, shares perspective on our commitment to patients and how it's led to the study of immune-mediated conditions.
-
Incyte
@Incyte
Learn more about how our @VoicesofMPN platform provides patients with the voice they need to share their story.
-
Incyte
@Incyte
#sciencespotlight: Our research portfolio includes the exploration & development of pan-inhibitors for PIM kinases.
-
Incyte
@Incyte
Our passions: people & science. Join our inspiring team to help make a difference in the lives of people affected by serious diseases. #lifeatincyte
-
Incyte
@Incyte
Our Chief Medical Officer, Steven Stein, shares his perspective on Incyte's commitment to continued research for the #rarecancer community. #rarecancerday
-
Incyte
@Incyte
We're spreading the #rarecancerday word to raise awareness of #rarecancers & remind patient communities that they not alone.
-
Incyte
@Incyte
Today, we recognize the first #rarecancerday hosted by @RareDiseases & emphasize our commitment to the #rarecancer community, including those living with #mpns & other serious diseases.
-
Incyte
@Incyte
We're honored to partner with advocacy organizations like @curecc to help raise awareness & offer support for the #rarecancer community. #rarecancerday
-
Incyte
@Incyte
Ahead of #rarecancerday, we recognize the importance of sharing stories among the #rarecancer community to help people living with an MPN, like Matt, feel heard. Read more about Matt's journey here: themighty.com/topic/rare-disease/what-ive-learned-since-m….
-
Incyte
@Incyte
Live at #esmo19: Dr. Arndt Vogel, M.D., Senior Consultant and Professor at Hannover Medical School, offers his perspective on how physicians can identify patients with #cholangiocarcinoma who have FGFR2 fusions or rearrangements.
-
Incyte
@Incyte
We’ve been recognized as a @PHLBizJournal #soaring76 – one of greater Philadelphia’s fastest-growing companies. Great to join our local industry colleagues tonight at the recognition ceremony.
-
Incyte
@Incyte
#breaking: We've announced the first patient treated in our Phase 3 program of a topical therapy for people living with vitiligo. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
Supporting and partnering with advocacy organizations who provide invaluable resources to patients and their families is a part of our DNA at Incyte. Learn more about patient resources. incyte.com/incyte-involved
-
Incyte
@Incyte
Our colleague & Director of Pharmacology, Maryanne, shares her insider perspective on life in the lab & breaking down the #science to better serve patients. #lifeatincyte incyte.com/join-us/join-incyte
-
Incyte
@Incyte
We're committed to creating a culture of patient-focused research fueled by critical thinking. #lifeatincyte incyte.com/join-us/join-incyte
-
Incyte
@Incyte
#sciencespotlight: PI3Kδ is an important anticancer target implicated in malignant B-cell growth, survival & migration and may also play a role in the development of resistance to therapies. We're exploring potential ways to inhibit PI3Kδ signaling. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
What comes to mind when our Head of HR, Paula Swain, thinks about #lifeatincyte? The people and patient impact.
-
Incyte
@Incyte
Our Group VP of Oncology Drug Development, Peter Langmuir, shares his perspective on why the earliest stages of research are pivotal in discovery. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte
@Incyte
On #mpnawarenessday & every day, we’re committed to further elevating awareness of MPNs to support the MPN community & make a difference in the lives of patients and caregivers. #act4mpn
Voices of MPN
@VoicesofMPN
Today we celebrate the strength and resiliency of people living with myeloproliferative neoplasms (MPNs).
-
Incyte
@Incyte
We know that the burden of #mpns on patients can be both challenging & discouraging. This #mpnawarenessday, we aim to activate, inspire & support the #mpn community. #act4mpn via @VoicesOfMPN. www.voicesofmpn.com
-
Incyte
@Incyte
Our global team of 600 scientists has enabled us to identify new molecules, decipher new pathways and develop innovative medicines.
-
Incyte
@Incyte
We believe in the value of investing in basic and translational research to drive the development of innovative medicines for patients.
-
Incyte
@Incyte
Over the last 16+ years, our science-first approach and heritage in #immunology has formed the foundation of our company. Learn more.
-
Incyte
@Incyte
#sciencespotlight: We're investigating FGFR inhibitors as important targets for anticancer drug development.
-
Incyte
@Incyte
Thank you @RMHDelaware for having us! Great to give back to our local community.
RMHC Greater Delaware
@RMHCDelaware
Thank you to the awesome volunteers from @Incyte who cooked a delicious lunch for our families yesterday!
-
Incyte
@Incyte
#lifeatincyte means digging deeper & working with a sense of urgency because we know patients are waiting.
-
Incyte
@Incyte
In honor of Blood Cancer Awareness Month, we've launched the #mympnchallenge to inspire & engage the #mpn community. Learn more & get involved via @VoicesOfMPN. investor.incyte.com/news-releases/news-release-details/in…
-
Incyte
@Incyte
We exist to improve the lives of people living with #cancer and inflammatory or autoimmune diseases. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte reposted
Voices of MPN
@VoicesofMPN
This September, participate in the #mympnchallenge to take action and support the #mpn patient community! For every challenge completed, @Incyte will make a donation to @LLSusa.
-
Incyte
@Incyte
We exist to improve the lives of people living with #cancer and inflammatory or autoimmune diseases. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte
@Incyte
We strive to continue to build on our learnings in JAK inhibition and are constantly seeking ways to positively impact the lives of more people. incyte.com
-
Incyte
@Incyte
Our targeted therapy discovery approach leverages cross-program knowledge throughout the R&D process to identify and exploit novel points of synergy. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
Our commitment to patients, caregivers and our own employees remains at the core of who we are. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte
@Incyte
Our #science includes the continued exploration of FGFR inhibition, which we believe serves an important role in tumor cell proliferation and survival, migration, and angiogenesis. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
We believe in the value of partnership and collaboration across all disciplines. Hear from Research Fellow, Discovery Chemistry, Eddy Yue, on Incyte's team dynamic. incyte.com/what-we-do/drug-development
-
Incyte
@Incyte
By collaborating with like-minded partners, we're able to share knowledge, resources and ideas that may benefit patients. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte
@Incyte
We foster a work environment that is both fun and rewarding. Hear more from Incyte Head of HR, Paula Swain, on our culture. incyte.com/join-us/join-incyte
-
Incyte
@Incyte
Our discovery approach ladders up to a portfolio that is strategically coherent and synergy-rich with molecules that are designed to be optimized for their intended use. incyte.com/what-we-do/drug-development
-
Incyte
@Incyte
Our commitment to science and innovation is at the core of everything we do to discover, develop, and deliver novel medicines that address unmet needs in oncology and other diseases. incyte.com/who-we-are/biopharmaceutical-research
-
Incyte
@Incyte
Life-saving clinical advances and discovery wouldn’t be possible without the basis of foundational research. Incredible new findings from @NIH on early stage cancer diagnosis
NIH
@NIH
News: NIH researchers uncover role of repetitive DNA and protein sequences in tumor evolution www.nih.gov/news-events/news-releases/nih-researchers-unc…
-
Incyte
@Incyte
Our research extends beyond #oncology research and we're leaning on past learnings to advance our science. Hear more from our Group VP, Inflammation & Autoimmunity, Jim Lee. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
#sciencespotlight: We are investigating molecules that have the potential to be important targets in hematologic malignancies as well as solid tumors. incyte.com/what-we-do/drug-discovery-process
-
Incyte
@Incyte
Our senior leaders Maria Pasquale and Paula Swain share their #hbaimpact & discuss what they believe helped them propel their careers. Learn more via @HBAnet. hbanet.org/news/2019/07/24/taking-risks-and-being-vulnera…
-
Incyte
@Incyte
If you have a passion for innovative science and want to make a difference, consider joining our team. incyte.com/join-us/join-incyte























































































































